[go: up one dir, main page]

WO2000006153A1 - Propenamides as ccr5 modulators - Google Patents

Propenamides as ccr5 modulators Download PDF

Info

Publication number
WO2000006153A1
WO2000006153A1 PCT/US1999/017117 US9917117W WO0006153A1 WO 2000006153 A1 WO2000006153 A1 WO 2000006153A1 US 9917117 W US9917117 W US 9917117W WO 0006153 A1 WO0006153 A1 WO 0006153A1
Authority
WO
WIPO (PCT)
Prior art keywords
propenamide
methylethyl
methoxyphenyl
amino
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017117
Other languages
French (fr)
Inventor
William E. Bondinell
Michael J. Neeb
Thomas W. Ku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to CA002338804A priority Critical patent/CA2338804A1/en
Priority to EP99937585A priority patent/EP1100495A4/en
Priority to JP2000562008A priority patent/JP2002521441A/en
Publication of WO2000006153A1 publication Critical patent/WO2000006153A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/29—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/44—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • This invention relates to substituted anilides which are modulators, agonists or antagonists, of the CC chemokine receptor CC-CKR5 now designated as CCR5 (Nature Medicine, 2: 1174-8, 1996). In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5.
  • T cells are not only key regulators of the immune response to infectious agents but are believed critical for the initiation and maintenance of the inflammatory reaction in a variety of chronic diseases.
  • Increased numbers or enhanced activation state of T cells, especially CD4+ T cells have been demonstrated in the synovium of individuals with rheumatoid arthritis (M.J. Elliott and R. N. Maini, Int. Arch. Allergy Immunol. 104: 112-1125, 1994), in the bronchial mucosa of asthmatics (C.J. Corrigan and A.B. Kay, Immunol. Today 13: 501-506, 1992), in the lesions of multiple sclerosis (R. Martin and H. F. McFarland, Crit. Rev.
  • T cells as well as other inflammatory cells, will migrate into tissues in response to the production of a variety of chemotactic factors.
  • chemokines a superfamily of 8-12 kDa proteins known as the chemokines. These proteins share structural features such as the presence of 3-4 conserved cysteine residues.
  • RANTES which stands for Regulated upon Activation Normal T cell Expressed and Secreted, is a 8 kDa protein member of CC branch of the chemokine family. These proteins recruit and activate immune and inflammatory cells through an interaction with G-protein coupled receptors.
  • the CC branch is defined by the absence of an intervening amino acid residue between the first two cysteine residues and members of this family predominately elicit the migration of mononuclear cells, eosinophils and basophils (M. Baggiolini, B. Dewald, and B. Moser, Adv. Immunol. 55: 97-179, 1994; and J.J. Oppenheim, C.O.C. Zachariae, N. Mukaida, and K. Matsushima, Annu. Rev. Immunol. 9: 617-648, 1991).
  • RANTES potently produces chemotaxis of T cells, basophils, eosinophils, monocytes and mast cells.
  • RANTES was originally identified as gene product induced late after antigen activation of T-cells (T.J. Schall, J. Jongstra, B J. Dyer, J. Jorgensen, et al., J. Immunol. 141:1018-1025, 1988), however, RANTES has been shown to be synthesized and secreted by a diverse group of cells that include epithelial and endothelial cells (C. Stellato, L.A. Beck, G.A. Gorgone, D. Proud, et al., J. Immunol.
  • RANTES mRNA is rapidly upregulated in response to IL-1 or TNF ⁇ .
  • RANTES mRNA is not usually detected in normal tissues (J.M. Pattison, P.J. Nelson, and A.M. Krensky, Clin. Immunother. 4: 1-8, 1995), increased mRNA or protein has been found in diseases characterized by a mononuclear infiltrate.
  • RANTES mRNA was visualized using in situ hybridization in renal allografts undergoing rejection (J.M. Pattison, P.J. Nelson, and A.M. Krensky, Clin. Immunother. 4: 1-8, 1995; and K.C. Nadeau, H. Azuma and N.I. Tilney, Proc. Natl. Acad. USA 92: 8729-8733, 1995) in the skin of atopic dermatitis patients after exposure to antigen (S. Ying, L. T presenteda-Barata, Q. Meng, M. Humbert, et al., J. Exp. Med.
  • CCR5 when expressed in either HEK 293 cells or CHO cells, binds RANTES. This receptor is expressed in T-cells and in monocytes and macrophages, immune/inflammatory cells which are important in the maintenance of a chronic inflammatory reaction.
  • Pharmacological characterization of CCR5 indicates similarities to the RANTES binding site observed on isolated T cells. Therefore, antagonism of RANTES' action on CCR5, as well as antagonism of other natural modulators of CCR5, should inhibit the recruitment and activation of T cells and macrophages into inflammatory lesions and provide a novel therapeutic approach for the treatment of atopic and autoimmune disorders.
  • T cells express CCR5, selective receptor modulators of CCR5, particularly antagonists, are likely to provide beneficial effects in diseases including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, preferably humans.
  • CD8+ T cells have been implicated in chronic obstructive pulmonary disorders (COPD)
  • COPD chronic obstructive pulmonary disorders
  • CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD.
  • CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.
  • the present invention is to novel compounds of formula (I), or pharmaceutically active salts thereof, and their novel use in treating the above- mentioned CCR5-mediated disease states:
  • the basic nitrogen in moiety E may be optionally quaternized with C ⁇ _ galkyl or is optionally present as the N-oxide
  • pl is phenyl, fused bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic heterocyclic ring of 8 to 11 members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur
  • L is CONR 5 ';
  • Rl' and R ⁇ ' are independently hydrogen, C ⁇ .galkyl, C2_6alkenyl, C2_
  • R 3 ' is hydrogen or C galkyl
  • R 4 ' is hydrogen, Ci .galkyl, C ⁇ _6 a tylCONH, or halogen;
  • R5 ' is hydrogen or C ⁇ .galkyl;
  • R ⁇ ' and R 7 ' are independently hydrogen or C1 _6alkyl, or R ⁇ ' and R 7 ' together with the nitrogen to which they are attached, forms a 5- to 6- membered heterocyclic ring, which may optionally be substituted by an oxo group, and, when there are six members, may optionally contain in the ring one oxygen or one sulfur atom;
  • R 8 ' is hydrogen, C ⁇ _5alkyl, or C ⁇ _4alkoxy alkyl
  • R 9 ', R 2 !', and R 28 ' are independently Ci.galkyl;
  • R 10 ' is C ⁇ _6alkyl or phenyl;
  • R* !' and R ⁇ 2 ' are independently hydrogen or C ⁇ alkyl, or R 1 1' and
  • Rl 2 ' together with the nitrogen to which they are attached form a 5- to 6- membered saturated heterocyclic ring which, when there are 6 ring members, may optionally contain in the ring one oxygen or one sulfur atom;
  • R 1 ' is C 1 _4alkyl , optionally substituted by a C ⁇ _6alkoxy ;
  • R 22' is hydrogen or C galkyl optionally substituted with one or two substituents selected from C galkyl, C galkoxy, hydroxy, or NR6'R7'; ⁇
  • R 2 ⁇ ' and R 2 ⁇ ' are independently hydrogen or C galkyl, or R 2 ⁇ ' and R26' together with the nitrogen to which they are attached form a 5- to 6- membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom;
  • R 29 ' and R 3 ⁇ ' are independently hydrogen or C ⁇ alkyl, or R 29 ' and
  • R30' together with the nitrogen to which they are attached form 5- to 6- membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or one sulfur atom;
  • R 32 ' is hydrogen, Ci ⁇ galkyl, C3_6cycloalkyl, C3.gcycloalkenyl, hydroxyC ⁇ _6alkyl, C galkylOCi.galkyl, CONR 33 'R 34 ', CO2R 35 ', cyano, aryl, trifluoromethyl, NR 3 6'R 37 ' ; nitro, hydroxy, C ⁇ _6alkoxy, C ⁇ alkanoyl, acyloxy, or halogen; R 33 ', R 34' , R 35 ', R 36 ', and R 37 ' are independently hydrogen or C ⁇ _
  • Rl and R 2 are independently hydrogen or Ci ⁇ alkyl; alternatively
  • B(CR!R 2 ) a is OCRiR ⁇ R ⁇ O ⁇ CRiR 2 or OCR 1 R 2 CR 1 (OCOCH 3 )CR 1 R 2 ;
  • R 3 and R 4 are independently hydrogen, C ⁇ .galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C ⁇ _6alkyl, aryl, CONR 10 R ⁇ , NR ⁇ R 1 1 , hydroxy, OCOR ⁇ 2 , NHCOCo-6alkyl where alkyl is optionally substituted by
  • R 5 is hydrogen, C ⁇ _ 6 alkyl, aryl, CN, CONR 15 R 16 , CO 2 R 17 , trifluoromethyl, NHCO2R 18 , hydroxy, C ⁇ _6alkoxy, benzyloxy, ⁇
  • R 7 , R 8 , RlO, Rl 1, R 12 , R 15 , R 16 , R 17 > R 20 , R 21 , R 22 , and R 23 are independently hydrogen or Cj.galkyl;
  • R 9 is hydrogen, C ⁇ alkyl, or phenylCj.galkyl;
  • R 13 , R 14 , R 18 , and R 19 are independently C ⁇ galkyl; a is 1, 2, 3, or 4; b is 1 or 2; c and d are independently 0, 1 or 2; e is 2, 3 or 4; f is O, 1, 2 or 3; alternatively, E represents (b):
  • R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 3 1 , and R 32 are independently hydrogen or C ⁇ alkyl
  • R 3 ⁇ is hydrogen, Ci .galkyl, or C3_7cycloalkyl
  • R 34 , R 35 , R 36 , R 37 , and R 38 are independently hydrogen or C ⁇ _ galkyl; g is 1, 2 or 3; h is 1, 2 or 3 i is 2, 3, or 4 j is O, 1, 2, or 3; k is 0, 1 or 2; alternatively, E represents (c):
  • R 39 and R 4 ⁇ are independently hydrogen or Ci _6alkyl;
  • R 41 is a group of formula (d):
  • R 4 1 is a group of formula (e):
  • R 42 is hydrogen, Ci ⁇ alkyl, aryl, CN, CONR 48 R 49 , CO R 50 , trifluoromethyl, NHCO2R ⁇ , hydroxy, C ⁇ .galkoxy, benzyloxy, OCH 2 CO 2 C 1 . 6 alkyl, OCF , S(O) s R 52 , SO 2 NR 53 R 54 , or halogen;
  • R 47 is hydrogen, C ⁇ _6alkyl, or C3.7 cycloalkyl;
  • R51 and R ⁇ 2 are independently C ⁇ _6alkyl; 1 is 0, 1, 2, or 3; m is 1 or 2; n is O, 1, or 2 o, p, and q are independently integers having the value 1, 2, or 3; r is 0,1, 2, or 3; s is O, 1, or 2; t is 2 or 3; alternatively, E represents (f):
  • R ⁇ 7 and R ⁇ 8 are independently hydrogen or C ⁇ _6alkyl
  • R ⁇ 9 and R ⁇ O are independently hydrogen, C ⁇ galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C ⁇ alkyl, aryl, CONR 61 R 62 , NR 61 R 62 , hydroxy, OCOR ⁇ 3 , NHCOC()-6alkyl where alkyl is optionally substituted by OH, NHCOCF3 , NHSO R 64 and NHCO 2 R 65 ;
  • T is -(CR 66 R 67 ) V - or -O(CR 66 R 67 ) w -;
  • R 61 , R 62 , R 63 , R 66 , R 67 R 68 , R 69 , and R70 are independently hydrogen or C ⁇ .galkyl;
  • R 64 and R 65 are independently C 1 _6alkyl ;
  • u is 1 to 4;
  • v is 2 or 3;
  • w is 1, 2, or 3;
  • x is 0, 1 or 2; alternatively, E represents a group (g):
  • R 7 1 is an optionally substituted 5 to 7-membered saturated or partially saturated heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur or R 71 is an optionally substituted 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulfur;
  • R 72 is hydrogen, C ⁇ alkyl, aryl, CN, CONR 74 R 75 , CO 2 R 76 , trifluoromethyl, NHCO2R 77 , hydroxy, Ci .galkoxy, benzyloxy, OCH 2 CO 2 C 1 _ 6 alkyl, OCF3, S(O) z R 78 , SO 2 NR 79 R 80 , or halogen;
  • R 73 is hydrogen, Ci .galkyl, hydroxy, C galkoxy or halogen, or R 73 and R ⁇ ' taken together from a group -X- where X is (CR 1 R 82 ) aa or X is
  • R 74 , R 75 , R 76 , R 79 , R 80 , R 81 , and R 82 are independently hydrogen or Cj.galkyl;
  • R 77 and R 78 are independently C ⁇ alkyl; y is 1 or 2; z is O, 1, or 2; aa is 2, 3 or 4; ab is 0, 1, 2 or 3; alternatively, E represents group (h):
  • R 83 and R 84 are independently hydrogen or Cj.galkyl
  • R 5 and R 8 ⁇ are independently hydrogen, C galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include Chalky!, aryl, CONR 88 R 89 , NR 90 R 91 , hydroxy, OCOR 92 , NHCOC()-6alkyl where alkyl is optionally substituted by OH, NHCOCF3, NHSO R 93 , and NHCO 2 R 94 ;
  • R 87 is hydrogen or C1.galkyl, C1 _6alkoxy, or halogen, or R 87 together with R ⁇ ' forms a group -AA- where AA is (CR 9 5R 6) a(j or ⁇ A j s
  • Z is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur;
  • R 88 , R 89 , R 90 , R 91 , R 92 , R 95 , and R 96 are independently hydrogen or Ci .galkyl;
  • R 93 and R 94 are independently Ci.galkyl; ac is 0 to 4; ad is 1, 2 or 3; ae is 0, 1 or 2; alternatively, E represents group (i):
  • R 97 and R 98 are independently hydrogen, C ⁇ alkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C ⁇ alkyl, aryl, CONR 102 R 103 , NR 104 R 105 , hydroxy, OCOR106, NHCOC Q - ⁇ alkyl where alkyl is optionally substituted by OH, NHCOCF3, NHSO 2 R 107 , and NHCO 2 R 108 ;
  • R 99 and RlOO are independently hydrogen or Cl-6alkyl;
  • R 101 is hydrogen or C ⁇ alkyl or R 101 and R ⁇ together form a group
  • AC is oxygen, CR 1 11R1 I 2 or NR ! 13 or AC is a group S(O)ak;
  • R l 13 are independently hydrogen or C _6alkyl ;
  • Rl° 7 and R 108 are independently Cl-6alkyl; af is O, 1, 2, 3, or 4; ag is 1, 2, or 3; ah is 1, 2, 3 or 4; ai is 2, 3 or 4; aj is 0, 1, 2, or 3; and ak is 0, 1 or 2.
  • the present invention is to a method of treating CCR5 mediated disease states, including, but not limited to, COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease and HIV infection, all in mammals, preferably humans, comprising administering to such mammal in need thereof, an anilide of formula (I), or pharmaceutically active salts thereof.
  • the present invention is to pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier therefor.
  • compositions of the present invention are used for treating CCR5-mediated disease states, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, COPD and HIV all in mammals, preferably humans.
  • substituted anilides of formula (I) are CCR5 receptor modulators. It has also now been discovered that selective inhibition of CCR5 receptor mechanisms by treatment with the receptor modulators of formula (I), or a pharmaceutically acceptable salt thereof, represents a novel therapeutic and preventative approach to the treatment of a variety of disease states, including, but not limited to, COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, preferably humans ("CCR5 -mediated diseases"). Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.
  • alkyl is used herein at all occurrences to mean a straight or branched chain radical of 1 to 6 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, and the like.
  • cycloalkyl and cyclic alkyl are used herein at all occurrences to mean cyclic radicals, preferably comprising 3 to 7 carbon atoms which may be mono- or bicyclo-fused ring systems which may additionally include unsaturation, including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • halo or halogen are used interchangeably herein at all occurrences to mean radicals derived from the elements chlorine, fluorine, iodine and bromine.
  • heterocyclic ring is used herein at all occurrences to mean a saturated or partially saturated 5-, 6-, or 7-membered ring system (unless the cyclic ring system is otherwise limited) in which the ring system contains one to 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which ring system may be optionally substituted with C ⁇ alkyl or C3_7cycloalkyl. Examples of such rings include, but are not limited to, piperidine, tetrahydropyridine, and piperazine.
  • heterocyclic ring When the heterocyclic ring is fused to a phenyl group, the term "heterocyclic ring", together with the phenyl ring to which it is fused, forms a ring which includes, but is not limited to, 1,2,3,4-tetrahydroquinoline, 2-oxo-benzoxazole, 3,4-dihydro-3-oxo-l,4- benzoxazine, 3,4-dihydro-l,4-benzoxazine, and 2,3-dihydro-indole, which may be optionally substituted by C ⁇ alkyl or oxo.
  • 6,6 or 6,5 bicyclic ring means a 6,6 or 6,5-bicyclic ring system containing a nitrogen atom and optionally a further heteroatom selected from nitrogen, oxygen, or sulfur, which ring system may be optionally substituted with Ci_6alkyl.
  • ring systems include, but are not limited to, tropane, isoquinuclidine and granatane rings.
  • CCR5 mediated disease state is used herein at all occurrences to mean any disease state which is mediated (or modulated) by CCR5.
  • the term "monocyclic heterocyclic ring” is used herein at all occurrences to mean a single aromatic ring of 5 to 7 members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur represented by pi and/or P 2 including thienyl, furyl, pyrrolyl, and pyridyl.
  • the term "fused bicyclic heterocyclic ring” is used herein at all occurrences to mean a fused bicyclic aromatic ring system of 8 to 11 -members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur including indole, benzofuran, benzothiophene, quinoline, and isoquinoline rings.
  • pharmaceutically acceptable salts of formula (I) include, but are not limited to, salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate, or salts with an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p- toluenesulfonate, palmitate, salicylate, and stearate.
  • inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate
  • an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p- toluenesulfonate, palmitate, salicylate, and stearate.
  • the compounds of the invention can exist in unsolvated as well as solvated forms, including hydrated forms.
  • solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, are equivalent to the unsolvated forms for purposes of this invention.
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms.
  • the stereocenters may be of any combination of R and S configuration, for example, (R,R), (R,S), (S,S) or (S,R). All of these compounds are within the scope of the present invention.
  • pl is suitably phenyl, fused bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic heterocyclic ring of 8 to 11 members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur.
  • pl is phenyl, naphthyl, furyl, thienyl, pyridyl, indolyl, benzofuranyl, and benzothienyl. More preferably, pl is phenyl and naphthalenyl. .
  • Rl ' is a 5- to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur
  • suitable heterocyclic rings include aromatic groups such as thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, and dioxanyl.
  • Saturated and partially saturated rings are also within the scope of the invention, in particular rings including an oxo or thioxo moiety such as lactams and thiolactams.
  • the heterocyclic ring can be linked to the remainder of the molecule via a carbon atom, or, when present, a nitrogen atom.
  • Suitable substituents for these rings include one to two of R 32 '.
  • L is suitably CONR 5 '.
  • Rl' and R 2 ' are suitably independently hydrogen, C ⁇ .galkyl, C2- galkenyl, C2-6 a lkynyl, C3_7cycloalkyl, C3_6cycloalkenyl, (CH2)b'NR ⁇ R ',
  • Rl' may also suitably be an optionally substituted, fused carbocyclic ring of 5 to 7-members, which may be partly or wholly unsaturated, or Rl' is an optionally substituted, fused heterocyclic ring of 5 to 7-members containing 1 to 4 heteroatoms selected from nitrogen, oxygen, or sulfur, which may be partly or wholly unsaturated.
  • Rl' is preferably hydrogen, C galkyl, a fused
  • R 2 ' is preferably hydrogen or halogen.
  • Rl ' is more preferably halogen, R 2 ' is more preferably halogen.
  • Rl ' and R 2 ' taken together are 3,4-dichloro or 3,5-dichloro.
  • R 3 ' is suitably hydrogen or C ⁇ alkyl.
  • R 3 ' is hydrogen.
  • R 4 ' is suitably hydrogen, Ci .galkyl, C galkylCONH, or halogen.
  • R 4 ' is hydrogen;
  • R 5 ' is suitably hydrogen or C galkyl.
  • R 5 ' is hydrogen.
  • R14' ? R15', R16' R17' ? R 18' t R19' R 20' > R 23', R24', R 27' ? and R 31' ⁇ suitably independently hydrogen or C ⁇ alkyl.
  • R ⁇ ' and R 7 ' are suitably independently hydrogen or Ci .galkyl, or R ⁇ ' and R 7 ' together with the nitrogen to which they are attached, forms a 5- to 6- membered heterocyclic ring, which may optionally be substituted by an oxo group, and, when there are six members, may optionally contain in the ring one oxygen or one sulfur atom.
  • R 8 ' is suitably hydrogen, Ci .galkyl or C ⁇ alkoxy alkyl.
  • R 9 ', R21 ', and R 28 are suitably independently C ⁇ .galkyl.
  • RlO' is suitably Chalky! or phenyl.
  • Rl 1' and Rl 2 ' are suitably independently hydrogen or C ⁇ galkyl, or
  • Rl 1 ' and Rl 2 ' together with the nitrogen to which they are attached form a 5- to 6-membered saturated heterocyclic ring which, when there are 6 ring members, may optionally contain in the ring one oxygen or one sulfur atom.
  • R 3 ' is suitably Ci _4alkyl, optionally substituted by a Ci .galkoxy.
  • R 22 ' is suitably hydrogen or Ci .galkyl optionally substituted with one or two substituents selected from Ci _galkyl, C ⁇ alkoxy, hydroxy, or NR 6 'R 7 '.
  • R 25 ' and R 2 ⁇ ' are suitably independently hydrogen or Cj.galkyl, or
  • R 25 ' and R ⁇ ' together with the nitrogen to which they are attached form a 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom.
  • R 29 ' and R 3 ⁇ ' are suitably independently hydrogen or C ⁇ _6alkyl, or
  • R 29 ' and R 3 ⁇ ' together with the nitrogen to which they are attached form 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom.
  • R3 2 ' is suitably hydrogen, Cj.galkyl, C3_gcycloalkyl, C3. gcycloalkenyl, hydroxyCi.galkyl, C ⁇ alkylOC ⁇ alkyl, CONR 3 3 R34' ; CO2R 35 ', cyano, aryl, trifluoromethyl, NR 3 ⁇ 'R 37 ', nitro, hydroxy, C ⁇ _ 6alkoxy, C ⁇ alkanoyl, acyloxy, or halogen.
  • R 33 ', R 34 ', R 35 ', R 3 ⁇ ', and R 37 ' are suitably independently hydrogen or C ⁇ _6alkyl.
  • a' is suitably 1, 2, or 3.
  • b' is suitably 1, 2, 3 or 4.
  • c' is suitably 0, 1, 2 or 3.
  • d' is suitably 1, 2 or 3.
  • E suitably represents (a):
  • B is preferably CR 7 R 8 , or oxygen. More preferably, B is CH2 or oxygen.
  • Rl and R 2 are suitably independently hydrogen or C1.galkyl.
  • Rl and R 2 are hydrogen.
  • B(CRlR ) a is OCRlR 2 CRl(OH)CR 1 R 2 or OCR 1 R CR 1 (OCOCH 3 )CR 1 R 2 .
  • B(CRlR 2 ) a is OCR 1 R 2 CR1(OCOCH 3 )CR1R 2
  • R 1 and R 2 are hydrogen.
  • R3 and R 4 are suitably independently hydrogen, C ⁇ .galkyl, C3. 7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include Cj.galkyl, aryl, CONRIORI 1,
  • R 3 and R 4 are both C ⁇ .galkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur. More preferably, R 3 and R 4 are C3_galkyl, or together with the nitrogen to which they are attached form a 6-membered ring, optionally substituted with one or more of Ci .galkyl, N-acetamido, or hydroxy.
  • R 3 and R 4 are both isopropyl or R 3 is isopropyl and R 4 is tert- butyl, or together with the nitrogen to which they are attached are 1 -(2,2,6,6- tetramethylpiperidinyl), l-(4-acetamido-2,2,6,6-tetramethylpiperidinyl), l-(4- hydroxy-2,2,6,6-tetramethylpiperidinyl), or 1 -(4-hydroxy-2,2,4,6,6- pentamethylpiperidinyl) .
  • B-(CR!R 2 ) a -NR 3 R 4 is ortho to R 5 , meta to L and para to
  • R6, and R 5 is para to L.
  • R 5 is suitably hydrogen, C ⁇ alkyl, aryl, CN, CONR 15 R 16 , CO 2 R 17 , trifluoromethyl, NHCO2R 18 , hydroxy, Cj.galkoxy, benzyloxy, OCH 2 CO 2 C 1 . 6 alkyl, OCF3, S(O) d Rl 9 , SO 2 NR 20 R 21 , or halogen.
  • R 5 is preferably C ⁇ .galkoxy, SCj.galkyl or halogen; more preferably methoxy, methylthio or iodo, most preferably methoxy. When R 5 is methoxy, it is preferably para to L.
  • R" is suitably hydrogen, Ci .galkyl, aryl, trifluoromethyl, hydroxy, C ⁇ _
  • R 6 is hydrogen.
  • R 7 , R 8 , R 10 , R 1 1 , R 12 , R 15 , R 16 , R 17 > R 20 , R 21 , R 22 , and R 23 are suitably independently hydrogen or Cj.galkyl.
  • R 9 is suitably hydrogen, C ⁇ .galkyl, or phenylCi _galkyl.
  • R13 ; R14 5 R18 5 and R19 ⁇ Q suitably independently C ⁇ _6alkyl.
  • a is suitably 1, 2, 3, or 4.
  • a is 2 or 3, more preferably, a is 2 or 3 when B is oxygen and a is 2 when B is CH2, most preferably, a is 2 when
  • B is oxygen.
  • b is suitably 1 or 2.
  • b is 1.
  • c and d are suitably independently 0, 1, or 2.
  • e is suitably 2, 3, or 4.
  • f is suitably 0, 1, 2, or 3.
  • E suitably represents (b):
  • R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 1 , and R 32 are suitably independently hydrogen or C ⁇ alkyl.
  • R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 31 , and R 32 are preferably hydrogen.
  • R 3 ⁇ is suitably hydrogen, C ⁇ alkyl, or C3_7cycloalkyl.
  • R 3 ⁇ is C ⁇ .galkyl, more preferably, R 3 ⁇ is C3_galkyl, most preferably, R ⁇ is isopropyl.
  • R 33 is suitably hydrogen, Ci .galkyl, trifluoromethyl, hydroxy or halogen, or R 33 and R 5 ' together form a group -K- where K is (CR 3 R 35 )j or
  • R33 i hydrogen.
  • J is suitably oxygen, CR36R37 5 or NR3 , or J is a group S(O)k.
  • J is oxygen.
  • J is para to L.
  • R 34 , R 3 5, R36 ; R37 ; R38 ⁇ g suitably independently hydrogen or C frustrating 6 alkyl.
  • g is suitably 1, 2, or 3.
  • g is 2 or 3, more preferably 2.
  • h is suitably 1, 2, or 3.
  • h is 1.
  • i is suitably 2, 3, or 4.
  • j is suitably 0, 1, 2, or 3.
  • k is suitably 0, 1 or 2.
  • a preferred subgenus of the compounds of formula (I) are compounds of formula (la) in which R 1 ', R 2 ', R 3 ', R 4 ', P 1 , a', L, R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , J, g, and h are defined as above:
  • the most preferred compounds of this invention are the following compounds: N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide;
  • B-CR 1 R 2 ) a -NR3R 4 is O-(CH 2 )3-N(CH 3 ) 2 ;
  • L is CONH;
  • R3', and R 4 ' are hydrogen; and P 1 is phenyl.
  • a further known subgenus of formula (I) is wherein:E is (a); B is para to L; B-(CR 1 R 2 ) a -NR3R 4 is S-(CH 2 )3-N(CH 3 ) 2 ; L is CONH; R5, R6, R 1 ', R 2 ', R3', and R 4 ' are hydrogen; and P is phenyl.
  • E is (a); B-(CR 1 R 2 ) a -NR R 4 is ortho to L; B is CH2, NCH3, oxygen, S, or SO2; R 1 and R 2 are hydrogen or methyl; a is 0-4; R3 and R 4 are independently hydrogen, C ⁇ alkyl, benzyl, or R3 and R 4 taken together with the nitrogen to which they are attached form a pyrrolidinyl, piperidinyl, morpholino, and (4- methyl- 1 -piperazinyl), (4-phenyl- 1 -piperazinyl), [4-(2-methoxyphenyl)- 1 - piperazinyl], [4-(4-methoxyphenyl)-l -piperazinyl], or [(4-fluorophenyl)-l- piperazine] ring; NR3R 4 is also present as a methochloride quaternary salt; R 5 is also present as a methochloride quaternary salt; R
  • R 1 ' and R 2 ' are independently hydrogen, methyl, trifluoromethyl, methoxy, fluoro, or chloro, all of which have been described in United States Patent 3,167,556, published January 26, 1965, United States Patent 3,201,401, published August 17, 1965, GB 1099829, published 17 January 1968, and Krapcho, et al., J. Med. Chem., 1969, 12, 164-6 as 5-HT inhibitors, and reported to have 5-HT inhibitory activity, and have been described in JP 05255291, published 5 October 1993, and reported to have calcium antagonist activity.
  • R 2 ', R3', and R 4 ' are hydrogen; and P 1 is 2-furyl, has been described in JP 45006533, published 5 March 1970, and reported to have anti-cancer activity.
  • Q-(CR 39 R 40 ) 1 -R 4 is -(CH 2 )2-3-( 2 -piperidinyl);
  • R 47 is methyl or ethyl;
  • R 42 is hydrogen or methoxy;
  • R 43 , Rl , R 2 ' and R 3 ' are hydrogen;
  • L is CONR 5 ';
  • R 4 ' and R 5 ' are independently hydrogen or methyl;
  • pl is phenyl, have been described in United States Patent 3,931,195, published January 6, 1976, and United States Patent 4,000,143, published December 28, 1976, as antiserotonin agents
  • E is (g); R 7 1 is meta to L; R 7 is (CQ-I alkyl- 1 -piperazine); R 72 is 4-methoxy; Rl' is bromo, phenyl, or 4- pyridinyl; R 73 , R 2 ', R 3 ', and R 4 ' are hydrogen; L is CONH; P 1 is phenyl or 3- thienyl,have been described in international patent application WO 95/06044, published 2 March 1995, as 5-HT1D receptor antagonists.
  • the pharmaceutically effective compounds of this invention are administered in conventional dosage forms prepared by combining a compound of formula (I) ("active ingredient") in an amount sufficient to treat asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic diseases, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, COPD, and HIV infection, with standard pharmaceutical carriers or diluents according to conventional procedures well known in the art. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • atopic disorders for example, atopic dermatitis and allergies
  • rheumatoid arthritis for example, atopic dermatitis and allergies
  • sarcoidosis and other fibrotic diseases for example, atopic dermatitis and allergies
  • psoriasis autoimmune diseases
  • autoimmune diseases such as multiple sclerosis,
  • the pharmaceutical carrier employed may be, for example, either a solid or liquid.
  • solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
  • time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1000 mg.
  • the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
  • the active ingredient may also be administered topically to a mammal in need of treatment or prophylaxis of CCR5 mediated disease states.
  • the amount of active ingredient required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the disease state being treated and the mammal undergoing treatment, and is ultimately at the discretion of the physician.
  • a suitable dose of an active ingredient is 1.5 mg to 500 mg for topical administration, the most preferred dosage being 1 mg to 100 mg, for example 5 to 25 mg administered two or three times daily.
  • topical administration non-systemic administration and includes the application of the active ingredient externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream.
  • systemic administration is meant oral, intravenous, intraperitoneal and intramuscular administration.
  • an active ingredient may be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation.
  • the active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e.g. from 1 % to 2% by weight of the formulation although it may comprise as much as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1% to 1% w/w of the formulation.
  • topical formulations of the present invention comprise an active ingredient together with one or more acceptable carrier(s) therefor and optionally any other therapeutic ingredient(s).
  • the carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous or alcoholic solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent.
  • the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C for half an hour.
  • the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of
  • bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
  • Lotions according to the present invention include those suitable for application to the skin or eye.
  • An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
  • Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis.
  • the basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol.
  • the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as esters or polyoxyethylene derivatives thereof.
  • suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as esters or polyoxyethylene derivatives thereof.
  • Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
  • the active ingredient may also be administered by inhalation.
  • inhalation is meant intranasal and oral inhalation administration.
  • Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.
  • the daily dosage amount of the active ingredient administered by inhalation is from about 0.1 mg to about 100 mg per day, preferably about 1 mg to about 10 mg per day.
  • this invention relates to a method of treating asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic diseases, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, COPD, and HIV infection, all in mammals, preferably humans, which comprises administering to such mammal an effective amount of a CCR5 receptor modulator, in particular, a compound as depicted in formula (I).
  • formula (I) compound can be administered to such mammal in a conventional dosage form prepared by combining the formula (I) compound with a conventional pharmaceutically acceptable carrier or diluent according to known techniques. It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.
  • the formula (I) compound is administered to a mammal in need of treatment for CCR5-mediated diseases in an amount sufficient to decrease symptoms associated with these diseases.
  • the route of administration may be oral or parenteral.
  • parenteral as used herein includes intravenous, intramuscular, subcutaneous, intra-rectal, intravaginal or intraperitoneal administration.
  • the subcutaneous and intramuscular forms of parenteral administration are generally preferred.
  • the daily parenteral dosage regimen will preferably be from about 30 mg to about 300 mg per day of active ingredient.
  • the daily oral dosage regimen will preferably be from about 100 mg to about 2000 mg per day of active ingredient. It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a formula (I) compound will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular mammal being treated, and that such optimums can be determined by conventional techniques.
  • suitably substituted 3-aryl or heteroaryl-2-propenoic acids are treated with a suitable reagent, such as thionyl chloride, at a suitable temperature, such as at reflux, to afford 3-aryl or heteroaryl-2-propenoyl chlorides, and the 3-aryl or heteroaryl-2-propenoyl chlorides are condensed with suitably substituted anilines in the presence of a suitable base, such as diisopropylethylamine, in a suitable solvent, such as dichloromethane, to give compounds of formula (I).
  • a suitable base such as diisopropylethylamine
  • a suitable solvent such as dichloromethane
  • the resin-bound aniline 1-4 is acylated with a commercially available or synthetically accessible 3-aryl- or heteroaryl-2-propenoic acid 1-5, for example, 3-(3,4-dichlorophenyl)-2-propenoic acid, using, for example, N-bromosuccinimide and triphenylphosphine in dichloromethane, or in dichloromethane in combination with dimethylformamide, in the presence of an organic base such as pyridine to afford 1-6.
  • a suitable reducing agent such as sodium triacetoxyborohydride
  • a suitable solvent such as dimethylformamide containing 1% acetic acid
  • 1-4 is treated with a tenfold excess of an equimolar mixture of a 3-aryl- or heteroaryl-2-propenoic acid, triphenylphosphine and N-bromosuccinimide, in a suitable solvent, such as dichloromethane, after which a ten-fold excess of a suitable base, such as pyridine, is added, and the mixture is gently agitated for a suitable time, for example, forty-eight hours, to afford the resin-bound amide 1-6.
  • dimethylformamide may be added to the resulting mixture to increase the solubility of the 3-aryl- or heteroaryl-2- propenoic acid.
  • 1-5 is converted to the acid chloride, for example by heating with thionyl chloride, and the acid chloride is condensed with 1-4 to afford I- 6.
  • a suitable acid such as trifluoroacetic acid:dichloromethane:water (50:48:2) gives 3-aryl- or heteroaryl-2-propenamides 1-7 which are compounds of formula (I).
  • Preparation 5 Preparation of 5-A ino-3-[2-[Bis(l-methylethyl)amino]ethyl1-2(3H)- benzoxazolone Following the procedure of Preparation 3(a)-(b), except substituting 5-nitro-2(3H)-benzoxazolone (WO 95/32967) for 6-nitro-2H-l,4- benzoxazin-3(4H)-one, gave the title compound.
  • Preparation 7 Preparation of 6-Amino-2,3-dihydro-N,N-bis( 1 -methylethyl)- lH-indole- 1 - ethanamine Following the procedure of Preparation 6(a)-(b), except substituting 2,3-dihydro-6-nitro-lH-indole for 7-nitro- 1,2,3,4- tetrahydroquinoline, gave the title compound.
  • Examples 6-12 Following the procedure of Example 5, except substituting 3-(5- indolyl)-2-propenoic acid, 3-(6-indolyl)-2-propenoic acid, •,•- dimethylcinnamic acid, •-(acetylamino)-3,4-dichlorocinnamic acid, 3-(5,6,7,8- tetrahydronaphth-2-yl)-2-propenoic acid, 4-chloro-3-methylcinnamic acid, and
  • Example 27 Preparation of N-r3-[3-[Bis(l-methylethyl)amino1propy ⁇ -4-methoxyphenvH- 3-(3,4-dichlorophenyl)-2-propenamide Following the procedure of Example 1, except substituting 3-[3-(diisopropylamino)propyl]-4-methoxyaniline (WO 99/01127) for 3-[2-(diisopropylamino)ethoxy]-4-methoxyaniline, gave the title compound. MS(ES) m/e 462.9 [M+H]+.
  • Example 28 Preparation of N-r3-[3-[Bis(l-methylethyl)amino1propy ⁇ -4-methoxyphenvH- 3-(3,4-dichlorophenyl)-2-propenamide Following the procedure of Example 1, except substituting 3-[3-(diisopropylamino)propyl]-4-methoxyaniline (WO 99/01127
  • Example 30(a) The resin of Example 30(a) was placed in an Irori MicroKan and treated with a ten-fold molar excess of an equimolar mixture of 4- chlorocinnamic acid, N-bromosuccinimide, and triphenylphosphine in dichloromethane, followed by addition of a ten-fold excess of pyridine. The mixture was gently agitated for 48 h after which the resin was washed three- times, sequentially with dimethylformamide, dichloromethane, and methanol to afford the title adduct.
  • Example 136 Preparation of N-[3-f2-[Bis( l-methylethyl)amino]ethoxy1-4-methoxyphenyll-3-(2- furanyl)-2-propenamide Following the procedure of Example 5, except substituting 3-(2-furanyl)-2-propenoic acid for 3-chlorocinnamic acid, afforded the title compound: MS(ES) m/e 387.1 [M+H]+. Examples 137-142
  • Example 143(a) The adduct of Example 143(a) (268.1 g) was stirred with dimethylformamide (1 under argon at RT for 30 min and tin(II) chloride dihydrate (133.5 g 0.59 mol) in dimethylformamide (1 L) was added in one portion. The mixture was stirred at RT under argon for 48 h, the resin was collected by filtration, and washed with 10% v/v hydrochlo acid:dioxane 1:1, 10% diisopropylethylamine in dimethylformamide, 50:50 dioxane:wate dioxane, dichloromethane, and methanol.
  • Example 143(b) A double Irori Kans was charged with the resin of Example 143(b) (100 mg) which was treated in dichloromethane with 3-(3,4-dichlorophenyl)-2-propenoic acid (12.3 mmol) followed by l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.36 g) and 1- hydroxybenzotriazole hydrate (1.88 g). The mixture was stirred at RT for 30 min.
  • Example 143(c) The resin of Example 143(c) was washed for 30 min with dimethylformamide whic was decanted, charged with dimethylformamide (100 mL), and treated with iodomethane (8 mmol). The mixture was stirred at RT for 48 h, the resin was removed and washed for 30 min with each of dimethylformamide, dioxane, dichloromethane, methanol, and diethyl eth The resin was dried in vacuo at RT, removed from the Kans, and treated with 10% triethylamine in dimethylformamide (1 mL) for 16 h with added Amberlyst-A21.
  • the mixture was filtered, treated with 1% triethylamine in dimethylformamide (1 mL), and agitated for 3 h.
  • the solvent was transferred by filtration, and the residue was washed with dimethylformamide (1 mL) for 1 h.
  • the solvent was concentrated in vacuo to afford the titl compound.
  • CCR5 Receptor Binding Assay CHO cell membranes (0.25 xlO 6 cell equivalents) derived from CHO cells stably transfected with CCR5 were incubated with 0.3 125 I- RANTES in a 96 well plate for 45 min at room temperature (final reaction volume 200 ul). The reaction was terminated by filtration and the filters (GF/C) were washed twelve times with a solution of phosphate buffered saline containing 0.1 % bovine serum albumin and 0.05 % NaN 3 . The radioactivity bound to filters was measured by liquid scintillation spectrometry. Non-specific binding was determined in the presence of unlabelled RANTES (10 or 30 nM) and averages 30-50% of total binding.
  • Agonist activity is determined by Ca 2+ mobilization in the same cells which is inhibitable by a selective CCR5 antagonist.
  • Krebs Ringer Henseleit buffer (KRH; 118 mM NaCl, 4.6 mM KC1, 25 mM NaHCO3, 1 mM KH2PO4 and 11 mM glucose) containing 5 mM HEPES (pH 7.4),
  • the compounds of this invention show CCR5 receptor modulator activity having IC50 values in the range of 0.0001 to 100 ⁇ M.
  • the full structure/activity relationship has not yet been established for the compounds of this invention.
  • one of ordinary skill in the art can utilize the present assays in order to determine which compounds of formula (I) are modulators of the CCR5 receptor and which bind thereto with an IC50 v lue in the range of

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

This invention relates to substituted anilides which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5.

Description

PROPENAMIDES AS CCR5 MODULATORS
*
FIELD OF THE INVENTION
This invention relates to substituted anilides which are modulators, agonists or antagonists, of the CC chemokine receptor CC-CKR5 now designated as CCR5 (Nature Medicine, 2: 1174-8, 1996). In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5.
BACKGROUND OF THE INVENTION T cells are not only key regulators of the immune response to infectious agents but are believed critical for the initiation and maintenance of the inflammatory reaction in a variety of chronic diseases. Increased numbers or enhanced activation state of T cells, especially CD4+ T cells, have been demonstrated in the synovium of individuals with rheumatoid arthritis (M.J. Elliott and R. N. Maini, Int. Arch. Allergy Immunol. 104: 112-1125, 1994), in the bronchial mucosa of asthmatics (C.J. Corrigan and A.B. Kay, Immunol. Today 13: 501-506, 1992), in the lesions of multiple sclerosis (R. Martin and H. F. McFarland, Crit. Rev. Clin. Lab. Sci. 32: 121- 182, 1995), in psoriatic lesions (J.L. Jones, J. Berth- Jone, A. Fletcher and P.E. Hutchinson, J. Pathol. 174: 77-82, 1994) and in the fatty streaks of atherosclerosis (R. Ross, Annu. Rev. Phvsiol. 57: 791-804, 1995).
T cells, as well as other inflammatory cells, will migrate into tissues in response to the production of a variety of chemotactic factors. Among these factors are a superfamily of 8-12 kDa proteins known as the chemokines. These proteins share structural features such as the presence of 3-4 conserved cysteine residues. RANTES, which stands for Regulated upon Activation Normal T cell Expressed and Secreted, is a 8 kDa protein member of CC branch of the chemokine family. These proteins recruit and activate immune and inflammatory cells through an interaction with G-protein coupled receptors. The CC branch is defined by the absence of an intervening amino acid residue between the first two cysteine residues and members of this family predominately elicit the migration of mononuclear cells, eosinophils and basophils (M. Baggiolini, B. Dewald, and B. Moser, Adv. Immunol. 55: 97-179, 1994; and J.J. Oppenheim, C.O.C. Zachariae, N. Mukaida, and K. Matsushima, Annu. Rev. Immunol. 9: 617-648, 1991).
RANTES potently produces chemotaxis of T cells, basophils, eosinophils, monocytes and mast cells. RANTES was originally identified as gene product induced late after antigen activation of T-cells (T.J. Schall, J. Jongstra, B J. Dyer, J. Jorgensen, et al., J. Immunol. 141:1018-1025, 1988), however, RANTES has been shown to be synthesized and secreted by a diverse group of cells that include epithelial and endothelial cells (C. Stellato, L.A. Beck, G.A. Gorgone, D. Proud, et al., J. Immunol. 155: 410-418, 1995; and A. Marfaing-Koka, O. Devergne, G. Gorgone, A. Portier, et al., J. Immunol. 154: 1870-1878, 1994), synovial fibroblasts (P. Rathanaswami, M. Hachicha, M. Sadick, T.J. Schall, et al., J. Biol. Chem. 268: 5834-5839, 1993) and dermal fibroblasts (M. Sticherling, M. Kupper, F. Koltrowitz, E. Bornscheuer, et al., J. Invest. Dermatol. 105: 585-591, 1995), mesangial cells (G. Wolf, S. Aberle, F. Thaiss, et al, Kidney Int. 44: 795-804, 1994) and platelets (Y. Koameyoshi, A. Dorschner, A.I. Mallet, E. Christophers, et al., J. Exp. Med. 176: 587-592, 1992). In these cells, RANTES mRNA is rapidly upregulated in response to IL-1 or TNFα. Although RANTES mRNA is not usually detected in normal tissues (J.M. Pattison, P.J. Nelson, and A.M. Krensky, Clin. Immunother. 4: 1-8, 1995), increased mRNA or protein has been found in diseases characterized by a mononuclear infiltrate. For example, RANTES mRNA was visualized using in situ hybridization in renal allografts undergoing rejection (J.M. Pattison, P.J. Nelson, and A.M. Krensky, Clin. Immunother. 4: 1-8, 1995; and K.C. Nadeau, H. Azuma and N.I. Tilney, Proc. Natl. Acad. USA 92: 8729-8733, 1995) in the skin of atopic dermatitis patients after exposure to antigen (S. Ying, L. Taborda-Barata, Q. Meng, M. Humbert, et al., J. Exp. Med. 181: 2153-2159, 1995), and in endothelial cells of coronary arteries undergoing accelerated atherosclerosis after cardiac transplant (J.M. Pattison, P.J. Nelson, and A.M. Krensky, Clin. Immunother. 4: 1-8, 1995). Further, increased immunoreactive protein for RANTES has been detected in bronchoalveolar lavage fluid (R. Alam, J. York, M. Boyers, et al., Am. J. Resp. Crit. Care Med. 149: A951, 1994) and sputum from asthmatic individuals (CM. Gelder, P.S. Thomas, D.H. Yates, LM. Adcock, et al., Thorax 50: 1033-1037, 1995).
Several receptors have been identified that bind RANTES. In particular, CCR5, when expressed in either HEK 293 cells or CHO cells, binds RANTES. This receptor is expressed in T-cells and in monocytes and macrophages, immune/inflammatory cells which are important in the maintenance of a chronic inflammatory reaction. Pharmacological characterization of CCR5 indicates similarities to the RANTES binding site observed on isolated T cells. Therefore, antagonism of RANTES' action on CCR5, as well as antagonism of other natural modulators of CCR5, should inhibit the recruitment and activation of T cells and macrophages into inflammatory lesions and provide a novel therapeutic approach for the treatment of atopic and autoimmune disorders. Since T cells express CCR5, selective receptor modulators of CCR5, particularly antagonists, are likely to provide beneficial effects in diseases including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, preferably humans. Furthermore, since CD8+ T cells have been implicated in chronic obstructive pulmonary disorders (COPD), CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.
Surprisingly, it has now been discovered that a class of non-peptide compounds, in particular substituted anilides of formula (I), function as CCR5 receptor modulators, and therefore, have utility in the treatment and prevention of disease states mediated by CCR5 receptor mechanisms.
SUMMARY OF THE INVENTION
In one aspect, the present invention is to novel compounds of formula (I), or pharmaceutically active salts thereof, and their novel use in treating the above- mentioned CCR5-mediated disease states:
Figure imgf000005_0001
wherein: the basic nitrogen in moiety E may be optionally quaternized with Cι_ galkyl or is optionally present as the N-oxide; pl is phenyl, fused bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic heterocyclic ring of 8 to 11 members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur; L is CONR5';
Rl' and R^' are independently hydrogen, C^.galkyl, C2_6alkenyl, C2_
6alkynyl, C3_7cycloalkyl, C3_6cycloalkenyl, (CH2) ' R^ R^', (CH2)b'NR6'COR8', (CH2)b'NR6'CO R9', (CH2)b'NR6'SO2R10', (CH2)b'CONR1 1'R12', hydroxyCi .galkyl, Ci^alkoxyalkyl (optionally substituted by a C^alkoxy or hydroxy group), (CH2)b'CO2Ci _6alkyl, (CH2)COC(O)R13', CR14'=NOR15', CNR16 =NOR15', COR17', CONR1 1 R12', CONR1 1'(CH2)d C1.4alkyl, CONR1 1'(CH )b'CO2R18', CONHNR 19^20'9 CONR 11 'SO2R21 ', CO2R22', cyano, trifluoromethyl, NR6'R7', NR6'C0R8', NR23'CO(CH2)b'NR23 R24', NR 3'CONR23'R24', NR6'CO2R9', NR6'SO2R10', N=CNR23 NR23'R24', nitro, hydroxy, Cχ_ galkoxy, hydroxyCι _6alkoxy, Ci.galkoxyC galkoxy, OC(O)NR25'R26', SR27', SOR28', SO2R28', SO2NR29'R30', halogen, C^alkanoyl, CO2(CH2)b R31 ', or R1 ' is phenyl or Rl ' is a 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur, which are optionally substituted by one or two of R32'; or Rl' is an optionally substituted, fused carbocyclic ring of 5 to 7- members, which may be partly or wholly unsaturated, or Rl' is an optionally substituted, fused heterocyclic ring of 5 to 7-members containing 1 to 4 heteroatoms selected from nitrogen, oxygen, or sulfur, which may be partly or wholly unsaturated;
R3' is hydrogen or C galkyl;
R4' is hydrogen, Ci .galkyl, Cι_6a tylCONH, or halogen; R5 ' is hydrogen or C \ .galkyl;
R14'f R15', Rlό' RlT Rl8', R19' R20 R23', R24', R27', and R31' ^ independently hydrogen or Cj.galkyl;
R^' and R7' are independently hydrogen or C1 _6alkyl, or R^' and R7' together with the nitrogen to which they are attached, forms a 5- to 6- membered heterocyclic ring, which may optionally be substituted by an oxo group, and, when there are six members, may optionally contain in the ring one oxygen or one sulfur atom;
R8' is hydrogen, Cι _5alkyl, or Cι_4alkoxy alkyl;
R9', R2!', and R28' are independently Ci.galkyl; R10' is Cι_6alkyl or phenyl;
R* !' and R^2' are independently hydrogen or C^alkyl, or R11' and
Rl2' together with the nitrogen to which they are attached form a 5- to 6- membered saturated heterocyclic ring which, when there are 6 ring members, may optionally contain in the ring one oxygen or one sulfur atom; R 1 ' is C 1 _4alkyl , optionally substituted by a C \ _6alkoxy ; R22' is hydrogen or C galkyl optionally substituted with one or two substituents selected from C galkyl, C galkoxy, hydroxy, or NR6'R7'; ^
R2^' and R2^' are independently hydrogen or C galkyl, or R2^' and R26' together with the nitrogen to which they are attached form a 5- to 6- membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom;
R29' and R3^' are independently hydrogen or C^alkyl, or R29' and
R30' together with the nitrogen to which they are attached form 5- to 6- membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or one sulfur atom;
R32' is hydrogen, Ci^galkyl, C3_6cycloalkyl, C3.gcycloalkenyl, hydroxyCι _6alkyl, C galkylOCi.galkyl, CONR33'R34', CO2R35', cyano, aryl, trifluoromethyl, NR36'R37'; nitro, hydroxy, Cι _6alkoxy, C^alkanoyl, acyloxy, or halogen; R33', R34', R35', R36', and R37' are independently hydrogen or C\_
6alkyl; a' is 1, 2, or 3; b' is 1, 2, 3 or 4; c' is O, 1, 2 or 3; d' is 1, 2 or 3;
E represents (a):
Figure imgf000007_0001
in which
B is oxygen, S(O)c, CR7=CR8, or CR7R8, or B is NR9; Rl and R2 are independently hydrogen or Ci^alkyl; alternatively
B(CR!R2)a is OCRiR^R^O^CRiR2 or OCR1R2CR1(OCOCH3)CR1R2;
R3 and R4 are independently hydrogen, C^.galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include Cι _6alkyl, aryl, CONR10Rπ, NR^R1 1, hydroxy, OCOR^2, NHCOCo-6alkyl where alkyl is optionally substituted by
OH, NHCOCF3, NHSO R13, and NHCO2R14; R5 is hydrogen, Cι_6alkyl, aryl, CN, CONR15R16, CO2R17, trifluoromethyl, NHCO2R18, hydroxy, Cι_6alkoxy, benzyloxy, φ
OCH2CO2C1_6alkyl, OCF3, S(O)dR19, SO2NR20R21 or halogen;
Figure imgf000008_0001
or halogen, or R^ taken together with R^' forms a group D where D is (CR22R )e or D is (CR22R23)f-G where G is oxygen, sulfur or
CR22=CR23, CR22=N, =CR22O, =CR22S, or =CR22-NR23;
R7, R8, RlO, Rl 1, R12, R15, R16, R17> R20, R21, R22, and R23 are independently hydrogen or Cj.galkyl; R9 is hydrogen, C^alkyl, or phenylCj.galkyl;
R13, R14, R18, and R19 are independently Cμgalkyl; a is 1, 2, 3, or 4; b is 1 or 2; c and d are independently 0, 1 or 2; e is 2, 3 or 4; f is O, 1, 2 or 3; alternatively, E represents (b):
Figure imgf000008_0002
R24, R25, R26, R27, R28, R29, R3 1, and R32 are independently hydrogen or C^alkyl;
R3^ is hydrogen, Ci .galkyl, or C3_7cycloalkyl;
R33 is hydrogen, Cj.galkyl, trifluoromethyl, hydroxy or halogen, or R33 and R5' together form a group -K- where K is (CR34R35) or K is (CR3 R35)j -M and M is oxygen, sulfur, CR34=CR35, CR34=N, or N=N; J is oxygen, CR36R37, or NR38, or J is a group S(O)k;
R34, R35, R36, R37, and R38 are independently hydrogen or Cι_ galkyl; g is 1, 2 or 3; h is 1, 2 or 3 i is 2, 3, or 4 j is O, 1, 2, or 3; k is 0, 1 or 2; alternatively, E represents (c):
Figure imgf000009_0001
in which:
Q is oxygen, S(O)n, CR44=CR45, CR44R45, or Q is NR46; R39 and R4^ are independently hydrogen or Ci _6alkyl; R41 is a group of formula (d):
Figure imgf000009_0002
(CH2)0 (CH2)p (CH2)q
N - (d)
or R41 is a group of formula (e):
Figure imgf000009_0003
R42 is hydrogen, Ci^alkyl, aryl, CN, CONR48R49, CO R50, trifluoromethyl, NHCO2R^, hydroxy, C^.galkoxy, benzyloxy, OCH2CO2C1.6alkyl, OCF , S(O)sR52, SO2NR53R54, or halogen;
R43 is hydrogen or R43 together with Rβ' forms a group R where R is CR55=CR56, CR55=CR56CR55R56, or (CR55R56)t;
R44, R45, R 6, R485 R49, R50, R53, R54? R55; and R56 ^ independently hydrogen or Cj.galkyl;
R47 is hydrogen, Cι_6alkyl, or C3.7 cycloalkyl; R51 and R^2 are independently Cι _6alkyl; 1 is 0, 1, 2, or 3; m is 1 or 2; n is O, 1, or 2 o, p, and q are independently integers having the value 1, 2, or 3; r is 0,1, 2, or 3; s is O, 1, or 2; t is 2 or 3; alternatively, E represents (f):
Figure imgf000010_0001
R^7 and R^8 are independently hydrogen or Cι _6alkyl;
R^9 and R^O are independently hydrogen, C^galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C^alkyl, aryl, CONR61R62, NR61R62, hydroxy, OCOR^3, NHCOC()-6alkyl where alkyl is optionally substituted by OH, NHCOCF3 , NHSO R64 and NHCO2R65 ;
T is -(CR66R67)V- or -O(CR66R67)w-;
W is oxygen, S(O)x, NR68, or W is CR69=CR70 or CR69R70;
R61, R62, R63, R66, R67 R68, R69, and R70 are independently hydrogen or C^.galkyl; R64 and R65 are independently C 1 _6alkyl ; u is 1 to 4; v is 2 or 3; w is 1, 2, or 3; x is 0, 1 or 2; alternatively, E represents a group (g):
R71
R» <«- (g);
R71 is an optionally substituted 5 to 7-membered saturated or partially saturated heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur or R71 is an optionally substituted 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulfur;
R72 is hydrogen, C^alkyl, aryl, CN, CONR74R75, CO2R76, trifluoromethyl, NHCO2R77, hydroxy, Ci .galkoxy, benzyloxy, OCH2CO2C1_6alkyl, OCF3, S(O)zR78, SO2NR79R80, or halogen; R73 is hydrogen, Ci .galkyl, hydroxy, C galkoxy or halogen, or R73 and R^' taken together from a group -X- where X is (CR 1R82)aa or X is
(CR81R82)ab-Y and Y is oxygen, sulfur or CR81=CR82;
R74, R75, R76, R79, R80, R81, and R82 are independently hydrogen or Cj.galkyl;
R77 and R78are independently C^alkyl; y is 1 or 2; z is O, 1, or 2; aa is 2, 3 or 4; ab is 0, 1, 2 or 3; alternatively, E represents group (h):
Figure imgf000011_0001
R87 (h);
R83 and R84 are independently hydrogen or Cj.galkyl;
R 5 and R8^ are independently hydrogen, C galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include Chalky!, aryl, CONR88R89, NR90R91, hydroxy, OCOR92, NHCOC()-6alkyl where alkyl is optionally substituted by OH, NHCOCF3, NHSO R93, and NHCO2R94;
R87 is hydrogen or C1.galkyl, C1 _6alkoxy, or halogen, or R87 together with R^' forms a group -AA- where AA is (CR95R 6)a(j or ^A js
(CR95=CR96)ae-AB and AB is oxygen, sulfur, CR 5=CR96, CR95=N,
CR95NR96 or N=N; Z is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur;
R88, R89, R90, R91, R92, R95, and R96 are independently hydrogen or Ci .galkyl;
R93 and R94 are independently Ci.galkyl; ac is 0 to 4; ad is 1, 2 or 3; ae is 0, 1 or 2; alternatively, E represents group (i):
Figure imgf000012_0001
R97 and R98 are independently hydrogen, C^alkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C^alkyl, aryl, CONR102R103, NR104R105, hydroxy, OCOR106, NHCOCQ-όalkyl where alkyl is optionally substituted by OH, NHCOCF3, NHSO2 R107, and NHCO2R108;
R99 and RlOO are independently hydrogen or Cl-6alkyl; R 101 is hydrogen or C^alkyl or R 101 and R^ together form a group
-AD- where AD is (CR109Rl l°)ai or AD is (CR1°9R1 l°)aj-AE and AE is oxygen, sulfur or CR1°9=CR11°;
AC is oxygen, CR111R1 I2 or NR! 13 or AC is a group S(O)ak; R1025 R103; R1045 R105, R106, R109, R110, RI I I. RI 12, and Rl 13 are independently hydrogen or C _6alkyl ;
Rl°7 and R108 are independently Cl-6alkyl; af is O, 1, 2, 3, or 4; ag is 1, 2, or 3; ah is 1, 2, 3 or 4; ai is 2, 3 or 4; aj is 0, 1, 2, or 3; and ak is 0, 1 or 2.
In another aspect, the present invention is to a method of treating CCR5 mediated disease states, including, but not limited to, COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease and HIV infection, all in mammals, preferably humans, comprising administering to such mammal in need thereof, an anilide of formula (I), or pharmaceutically active salts thereof. In yet another aspect, the present invention is to pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier therefor. In particular, the pharmaceutical compositions of the present invention are used for treating CCR5-mediated disease states, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, COPD and HIV all in mammals, preferably humans.
DETAILED DESCRIPTION OF THE INVENTION
It has now been discovered that substituted anilides of formula (I) are CCR5 receptor modulators. It has also now been discovered that selective inhibition of CCR5 receptor mechanisms by treatment with the receptor modulators of formula (I), or a pharmaceutically acceptable salt thereof, represents a novel therapeutic and preventative approach to the treatment of a variety of disease states, including, but not limited to, COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, preferably humans ("CCR5 -mediated diseases"). Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.
The term "alkyl" is used herein at all occurrences to mean a straight or branched chain radical of 1 to 6 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, and the like.
The terms "cycloalkyl" and "cyclic alkyl" are used herein at all occurrences to mean cyclic radicals, preferably comprising 3 to 7 carbon atoms which may be mono- or bicyclo-fused ring systems which may additionally include unsaturation, including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, and the like.
The terms "halo" or "halogen" are used interchangeably herein at all occurrences to mean radicals derived from the elements chlorine, fluorine, iodine and bromine. The term "heterocyclic ring" is used herein at all occurrences to mean a saturated or partially saturated 5-, 6-, or 7-membered ring system (unless the cyclic ring system is otherwise limited) in which the ring system contains one to 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which ring system may be optionally substituted with C^alkyl or C3_7cycloalkyl. Examples of such rings include, but are not limited to, piperidine, tetrahydropyridine, and piperazine. When the heterocyclic ring is fused to a phenyl group, the term "heterocyclic ring", together with the phenyl ring to which it is fused, forms a ring which includes, but is not limited to, 1,2,3,4-tetrahydroquinoline, 2-oxo-benzoxazole, 3,4-dihydro-3-oxo-l,4- benzoxazine, 3,4-dihydro-l,4-benzoxazine, and 2,3-dihydro-indole, which may be optionally substituted by C^alkyl or oxo.
The term "6,6 or 6,5 bicyclic ring" means a 6,6 or 6,5-bicyclic ring system containing a nitrogen atom and optionally a further heteroatom selected from nitrogen, oxygen, or sulfur, which ring system may be optionally substituted with Ci_6alkyl. Examples of such ring systems include, but are not limited to, tropane, isoquinuclidine and granatane rings.
The term "CCR5 mediated disease state" is used herein at all occurrences to mean any disease state which is mediated (or modulated) by CCR5.
The term "monocyclic heterocyclic ring" is used herein at all occurrences to mean a single aromatic ring of 5 to 7 members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur represented by pi and/or P2 including thienyl, furyl, pyrrolyl, and pyridyl. The term "fused bicyclic heterocyclic ring" is used herein at all occurrences to mean a fused bicyclic aromatic ring system of 8 to 11 -members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur including indole, benzofuran, benzothiophene, quinoline, and isoquinoline rings.
Suitably, pharmaceutically acceptable salts of formula (I) include, but are not limited to, salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate, or salts with an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p- toluenesulfonate, palmitate, salicylate, and stearate.
The compounds of the invention can exist in unsolvated as well as solvated forms, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol, and the like, are equivalent to the unsolvated forms for purposes of this invention.
The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. The stereocenters may be of any combination of R and S configuration, for example, (R,R), (R,S), (S,S) or (S,R). All of these compounds are within the scope of the present invention.
It will be understood by one skilled in the art that for 3-aryl or 3-heteroaryl-2- propenanilides of this invention, the geometry around the propenoyl double bond is trans or (E) unless the geometry is specified to be cis or (Z). For compounds of formula (I) various embodiments are as follows. It will be understood that the basic nitrogen in moiety E may be optionally quaternized with C^.galkyl or is optionally present as the N-oxide. p is suitably phenyl, fused bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic heterocyclic ring of 8 to 11 members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur. Preferably, pl is phenyl, naphthyl, furyl, thienyl, pyridyl, indolyl, benzofuranyl, and benzothienyl. More preferably, pl is phenyl and naphthalenyl. . When Rl ' is a 5- to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, suitable heterocyclic rings include aromatic groups such as thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, and dioxanyl. Saturated and partially saturated rings are also within the scope of the invention, in particular rings including an oxo or thioxo moiety such as lactams and thiolactams. Suitably, the heterocyclic ring can be linked to the remainder of the molecule via a carbon atom, or, when present, a nitrogen atom. Suitable substituents for these rings include one to two of R32'. L is suitably CONR5'.
Rl' and R2' are suitably independently hydrogen, C^.galkyl, C2- galkenyl, C2-6alkynyl, C3_7cycloalkyl, C3_6cycloalkenyl, (CH2)b'NR^R ',
(CH2)aNR6'COR8', (CH2)b'aNR6'CO2R9', (CH2)b'NR6'SO2R10',
(CH2)b'CONRl 1 Rl2', hydroxyCi .galkyl, C^alkoxy alkyl (optionally substituted by a C^alkoxy or hydroxy group), (C^^C^Cj.galkyl, (CH2)COC(O)R13', CR14'=NOR15', CNR16'=N0R15', COR17', CONRH 'R 2', CONR1
Figure imgf000015_0001
CONR1 1'(CH2)b'CO2Rl8', CONHNRl9'R20', CONRn'SO2R21', CO2R22', cyano, trifluoromethyl, NR6'R7', NR6'C0R8', NR23'CO(CH2)b'NR23'R24', NR23'CONR 3'R24', NR6'CO2R9', NR6'S02R10', N=CNR23'NR23'R24', nitro, hydroxy, Cι _ galkoxy, hydroxyCι _6alkoxy, Ci.galkoxyCμgalkoxy, OC(O)NR25'R26', SR27', SOR28', SO R28', SO2NR 9'R30', halogen, C^alkanoyl, CO2(CH2)b R 1 ', or Rl ' is phenyl or Rl ' is a 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur, which are optionally substituted by one or two of R32'. Rl' may also suitably be an optionally substituted, fused carbocyclic ring of 5 to 7-members, which may be partly or wholly unsaturated, or Rl' is an optionally substituted, fused heterocyclic ring of 5 to 7-members containing 1 to 4 heteroatoms selected from nitrogen, oxygen, or sulfur, which may be partly or wholly unsaturated. Rl' is preferably hydrogen, C galkyl, a fused
3,4-(tetramethylene) moiety, or halogen; R2' is preferably hydrogen or halogen. Rl ' is more preferably halogen, R2' is more preferably halogen. Most preferably, Rl ' and R2' taken together are 3,4-dichloro or 3,5-dichloro. R3' is suitably hydrogen or C^alkyl. Preferably, R3' is hydrogen. R4' is suitably hydrogen, Ci .galkyl, C galkylCONH, or halogen.
Preferably, R4' is hydrogen;.
R5' is suitably hydrogen or C galkyl. Preferably R5' is hydrogen. R14'? R15', R16' R17'? R18't R19' R20'> R23', R24', R27'? and R31' ^ suitably independently hydrogen or C^alkyl. R^' and R7' are suitably independently hydrogen or Ci .galkyl, or R^' and R7' together with the nitrogen to which they are attached, forms a 5- to 6- membered heterocyclic ring, which may optionally be substituted by an oxo group, and, when there are six members, may optionally contain in the ring one oxygen or one sulfur atom. R8' is suitably hydrogen, Ci .galkyl or C^alkoxy alkyl.
R9', R21 ', and R28 are suitably independently C^.galkyl.
RlO' is suitably Chalky! or phenyl.
Rl 1' and Rl2' are suitably independently hydrogen or C^galkyl, or
Rl 1 ' and Rl2' together with the nitrogen to which they are attached form a 5- to 6-membered saturated heterocyclic ring which, when there are 6 ring members, may optionally contain in the ring one oxygen or one sulfur atom. R 3' is suitably Ci _4alkyl, optionally substituted by a Ci .galkoxy.
R22'is suitably hydrogen or Ci .galkyl optionally substituted with one or two substituents selected from Ci _galkyl, C^alkoxy, hydroxy, or NR6'R7'.
R25' and R2^' are suitably independently hydrogen or Cj.galkyl, or
R25' and R ^' together with the nitrogen to which they are attached form a 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom. R29' and R3^' are suitably independently hydrogen or C ι_6alkyl, or
R29' and R3^' together with the nitrogen to which they are attached form 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom.
R32' is suitably hydrogen, Cj.galkyl, C3_gcycloalkyl, C3. gcycloalkenyl, hydroxyCi.galkyl, C^alkylOC^alkyl, CONR33 R34'; CO2R35', cyano, aryl, trifluoromethyl, NR3^'R37', nitro, hydroxy, Cι_ 6alkoxy, C^alkanoyl, acyloxy, or halogen.
R33', R34', R35', R3^', and R37' are suitably independently hydrogen or Cι _6alkyl. a' is suitably 1, 2, or 3. b' is suitably 1, 2, 3 or 4. c' is suitably 0, 1, 2 or 3. d' is suitably 1, 2 or 3.
E suitably represents (a):
Figure imgf000017_0001
wherein:
B is suitably oxygen, S(O)c, CR7=CR8> or CR7R8, or B is NR9. B is preferably CR7R8, or oxygen. More preferably, B is CH2 or oxygen.
Rl and R2 are suitably independently hydrogen or C1.galkyl.
Preferably, Rl and R2 are hydrogen. Alternatively, B(CRlR )a is OCRlR2CRl(OH)CR1R2 or OCR1R CR1(OCOCH3)CR1R2. Preferably, when B(CRlR2)a is OCR1R2CR1(OCOCH3)CR1R2, R1 and R2 are hydrogen.
R3 and R4 are suitably independently hydrogen, C^.galkyl, C3. 7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include Cj.galkyl, aryl, CONRIORI 1,
NR10Rl 1, hydroxy, OCOR12, NHCOCQ-6alkyl where alkyl is optionally substituted by OH, NHCOCF3, NHSO2 R13, and NHCO2RI4 Preferably R3 and R4 are both C \ .galkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur. More preferably, R3 and R4 are C3_galkyl, or together with the nitrogen to which they are attached form a 6-membered ring, optionally substituted with one or more of Ci .galkyl, N-acetamido, or hydroxy. Most preferably, R3 and R4 are both isopropyl or R3 is isopropyl and R4 is tert- butyl, or together with the nitrogen to which they are attached are 1 -(2,2,6,6- tetramethylpiperidinyl), l-(4-acetamido-2,2,6,6-tetramethylpiperidinyl), l-(4- hydroxy-2,2,6,6-tetramethylpiperidinyl), or 1 -(4-hydroxy-2,2,4,6,6- pentamethylpiperidinyl) .
Preferably, B-(CR!R2)a-NR3R4 is ortho to R5, meta to L and para to
R6, and R5 is para to L. R5 is suitably hydrogen, C^alkyl, aryl, CN, CONR15R16, CO2R17, trifluoromethyl, NHCO2R18, hydroxy, Cj.galkoxy, benzyloxy, OCH2CO2C1.6alkyl, OCF3, S(O)dRl9, SO2NR20R21, or halogen. R5 is preferably Cι .galkoxy, SCj.galkyl or halogen; more preferably methoxy, methylthio or iodo, most preferably methoxy. When R5 is methoxy, it is preferably para to L.
R" is suitably hydrogen, Ci .galkyl, aryl, trifluoromethyl, hydroxy, C\_
6alkoxy, or halogen, or R^ taken together with R5' forms a group D where D is (CR22R23)e or D is (CR22R23)f-G where G is oxygen, sulfur, or
CR22=CR23, CR22=N, =CR22O, =CR22S, or =CR22-NR23. Preferably, R6 is hydrogen.
R7, R8, R10, R1 1, R12, R15, R16, R17> R20, R21, R22, and R23 are suitably independently hydrogen or Cj.galkyl.
R9 is suitably hydrogen, C^.galkyl, or phenylCi _galkyl.
R13; R145 R185 and R19 ^Q suitably independently Cι _6alkyl. a is suitably 1, 2, 3, or 4. Preferably, a is 2 or 3, more preferably, a is 2 or 3 when B is oxygen and a is 2 when B is CH2, most preferably, a is 2 when
B is oxygen. b is suitably 1 or 2. Preferably, b is 1. c and d are suitably independently 0, 1, or 2. e is suitably 2, 3, or 4. f is suitably 0, 1, 2, or 3. alternatively, E suitably represents (b):
Figure imgf000018_0001
R24, R25, R26, R27, R28, R29, R 1, and R32 are suitably independently hydrogen or C^alkyl. R24, R25, R26, R27, R28, R29, R31, and R32 are preferably hydrogen.
R3^ is suitably hydrogen, C^alkyl, or C3_7cycloalkyl. Preferably, R3^ is C^.galkyl, more preferably, R3^ is C3_galkyl, most preferably, R ^ is isopropyl.
R33 is suitably hydrogen, Ci .galkyl, trifluoromethyl, hydroxy or halogen, or R33 and R5' together form a group -K- where K is (CR3 R35)j or
K is (CR34R35)j -M and M is oxygen, sulfur, CR34=CR35, CR34=N, or N=N. Preferably, R33 is hydrogen.
J is suitably oxygen, CR36R375 or NR3 , or J is a group S(O)k.
Preferably, J is oxygen. Preferably, J is para to L.
R34, R35, R36; R37; R38 ^g suitably independently hydrogen or C „ 6alkyl. g is suitably 1, 2, or 3. Preferably, g is 2 or 3, more preferably 2. h is suitably 1, 2, or 3. Preferably, h is 1. i is suitably 2, 3, or 4. j is suitably 0, 1, 2, or 3. k is suitably 0, 1 or 2. A preferred subgenus of the compounds of formula (I) are compounds of formula (la) in which R1', R2', R3', R4', P1, a', L, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, J, g, and h are defined as above:
Figure imgf000019_0001
Formula (la)
Among the preferred compounds of this invention are the following compounds:
N- [3 - [2- [Bis ( 1 -methylethy l)amino] ethoxy ] -4-methoxyphenyl] -3 - phenyl-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide; N-[4-Methoxy-3-[(2S)-(l-methyl-2-pyrrolidinyl)methoxy]phenyl]-3- (4-methylphenyl)-2-propenamide;
N-[4-Methoxy-3-[(2S)-(l-methyl-2-pyrrolidinyl)methoxy]phenyl]-3- (3 ,4-dichlorophenyl)-2-propenamide ; N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- chlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide hydrochloride;
N-[3-[2-(2,2,6,6-Tetramethylpiperidin-l-yl)ethoxy]-4-methoxy- phenyl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide; N-[l-[2-[Bis(l-methylethyl)amino]ethyl]-l,2,3,4-tetrahydroquinol-7- yl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3- chloropheny l)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3- chlorophenyl)-2-propenarnide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3- (3-chlorophenyl)-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxy- phenyl]-3-(3-chlorophenyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- chlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- chlorophenyl)-2-propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3- (4-chlorophenyl)-2-propenamide;
N-[3-t2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxy- phenyl]-3-(4-chlorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-[(3,4- methylenedioxy)phenyl]-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[(3,4- methylenedioxy)phenyl]-2-propenamide; N-[3-[3-[Bis( 1 -methylethyl)amino]propoxy]-4-methoxyphenyl]-3- [(3,4-methylenedioxy)phenyl]-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxy- phenyl]-3-[(3,4-methylenedioxy)phenyl]-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(3,4- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3- (3,4-difluorophenyl)-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxy- phenyl]-3-(3,4-difluorophenyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(2- naphthalenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxy- phenyl]-3-(2-naphthalenyl)-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (3-chlorophenyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethyl]-2-oxo-(3H)-benzoxazol-5- yl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[4-[2-[Bis(l-methylethyl)amino]ethyl]-3,4-dihydro-3-oxo-2H-l,4- benzoxazin-6-yl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[4-[2-[Bis( l-methylethyl)amino]ethyl]-3,4-dihydro-2H- 1 ,4- benzoxazin-6-yl]-3-(3,4-dichlorophenyhl-2-propenamide;
N-[2,3-Dihydro-l-[2-[bis(l-methylethyl)amino]ethyl]-lH-indol-6-yl]- 3-(3,4-dichlorophenyl)-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (5-indolyl)-2-propenamide; (E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl)-3-
(6-indolyl)-2-propenamide; (E)-»»»-Dimethyl-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4- methoxyphenyl]-3-phenyl-2-propenamide;
(Z)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl)-»- (acetylamino)-3-(3,4-dichlorophenyl)-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)]-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (5,6,7, 8-tetrahydronaphth-2-yl)-2-propenamide trifluoroacetate salt;
N-(Spiro[benzofuran-3(2H),4'-piperidin]-5-yl)-3-(3,4- dichlorophenyl)-2-propenamide;
N-[l'-(Isopropyl)spiro[benzofuran-3(2H)4'-piperidin]-5-yl]-3-(3,4- dichlorophenyl)-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]- 3-(4-chloro-3-methylphenyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxypheny]-3-(4- fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[4- (trifluoromethyl)phenyl]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-[3- (trifluoromethyl)phenyl]-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[3- (trifluoromethyl)phenyl]-2-propenamide;
N- [3 - [3 - [B is( 1 -methylethy l)amino]propoxy ] -4-methoxyphenyl] -3- [3 - (trifluoromethyl)phenyl]-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- chlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2- chlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- chlorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,4- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,4- dichlorophenyl)-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,4- dichlorophenyl)]-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,6- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,6- dichlorophenyl)-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,6- dichlorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,5- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,5- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,5- difluorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,5- difluorophenyl)-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,5- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,5- difluorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,4- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,4- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,4- difluorophenyl)]-2-propenamide(SB-383258); N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3- fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3- fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3- fluorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- chloro-6-fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2- chloro-6-fluorophenyl)-2-propenamide; N-[3-[3-[Bis( 1 -methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- chloro-6-fluorophenyl)]-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- bromo-2-fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l -methylethyl)amino]propy 1] -4-methoxyphenyl] -3 -(4- bromo-2-fluorophenyl)-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- bromo-2-fluorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- chloro-2-fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l -methylethy l)amino]propy 1] -4-methoxyphenyl] -3 -(4- chloro-2-fluorophenyl)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- chloro-2-fluorophenyl)]-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- chloro-4-fluorophenyl)-2-propenamide N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2- chloro-4-fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- chloro-4-fluorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,6- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,6- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,6- difluorophenyl)]-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- bromophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- bromophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- bromophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- chloro-3 -nitrophenyl)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- chloro-3-nitrophenyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-[4-(l- methy lethy l)pheny 1] -2-propenamide ; N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[4-(l- methylethyl)phenyl]-2-propenamide;
«
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-[4- ( 1 -methylethyl)phenyl]-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(5- bromo-2-methoxyphenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(5- bromo-2-methoxyphenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-([l,l - biphenyl]-4-yl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3- ([l,r-biphenyl]-4-yl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,3- dihydro- 1 H-inden-5-yl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3- bromo-4-fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3- bromo-4-fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3- bromo-4-fluorophenyl)]-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (3,5-dichlorophenyl)-2-propenamide trifluoroacetate;
N- [3- [3 - [Bis( 1 -methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3 ,5- dichlorophenyl)-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,5- dichlorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dimethylphenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- dimethylphenyl)-2-propenamide
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,4- dimethylphenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- cyanophenyl)-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- cyanophenyl)-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- cyanophenyl)]-2-propenamide;
N-[3-[2-[Bis( 1 -methylethyl)amino]ethoxy]-4-methoxyphenyl]-2- fluoro-3-phenyl-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-2- fluoro-3-phenyl-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-2- fluoro-3-phenyl-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- [4-chloro-3-(trifluoromethyl)phenyl]-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (3,4-dichlorophenyl)-»-methyl-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- [4-(trifluoromethyl)phenyl]-2-propenamide; N-[3-[2-Acetoxy-3-[bis(l-methylethyl)amino]propoxy]-4- methoxyphenyl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[3-[2-(4-Hydroxy-2,2,6,6-tetramethylpiperidin-l-yl)ethoxy]- 4-methoxyphenyl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[l'-(l-Methylethyl)spiro[benzofuran-3(2H)4'-piperidin]-5-yl]-3-(3,5- dichlorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3- thienyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3-thienyl)- 2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3- thienyl)-2-propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(3- thienyl)-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]-3-(3- thienyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(4-pyridinyl)- 2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- pyridinyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3-furanyl)-
2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(3-furanyl)-2- propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3-furanyl)- 2-propenamide; N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(3- furanyl)-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]-3-(3- furanyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2-thienyl)- 2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- thienyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2-furanyl)- 2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(lH- indol-3-yl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(lH-indol-2- y l)-2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(l-methyl- lH-indol-2-yl)-2-propenamide;
N-[3-[2-[Bis( 1 -methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (benzo[b]thien-3-yl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- benzofuranyl)-2-propenamide; and N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-
(benzo[b]thien-2-yl)-2-propenamide.
Among the more preferred compounds of this invention are the following compounds:
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- phenyl-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide hydrochloride; N-[3-[2-(2,2,6,6-Tetramethylpiperidin-l-yl)ethoxy]-4-methoxy- phenyl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide; N-[l-[2-[Bis(l-methylethyl)amino]ethyl]-l,2,3,4-tetrahydroquinol-7- yl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3- chlorophenyl)-2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- chlorophenyl)-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxy- phenyl]-3-(4-chlorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide; N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-
(3,4-difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxy- phenyl]-3-(2-naphthalenyl)-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (3-chlorophenyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethyl]-2-oxo-(3H)-benzoxazol-5- yl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[4-[2-[Bis(l-methylethyl)amino]ethyl]-3,4-dihydro-3-oxo-2H-l,4- benzoxazin-6-yl]-3-(3,4-dichlorophenyl)-2-propenamide;
N- [2,3-Dihydro- 1 - [2- [bis( 1 -methylethyl)amino]ethyl]- 1 H-indol-6-yl]- 3-(3,4-dichlorophenyl)-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (5,6,7,8-tetrahydronaphth-2-yl)-2-propenamide trifluoroacetate salt;
N-[l'-(Isopropyl)spiro[benzofuran-3(2H)4'-piperidin]-5-yl]-3-(3,4- dichlorophenyl)-2-propenamide; (E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-
3-(4-chloro-3-methylphenyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,5- difluorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- bromophenyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3- bromo-4-fluorophenyl)-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (3 ,5-dichlorophenyl)-2-propenamide trifluoroacetate;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,5- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,5- dichlorophenyl)]-2-propenamide;
N-[3-[2-Acetoxy-3-[bis(l-methylethyl)amino]propoxy]-4- methoxyphenyl]-3-(3,4-dichlorophenyl)-2-propenamide; N-[3-[2-(4-Hydroxy-2,2,6,6-tetramethylpiperidin-l-yl)ethoxy]-
4-methoxyphenyl]-3-(3,4-dichlorophenyl)-2-propenamide; and
N-[ 1 '-( 1 -Methylethyl)spiro[benzofuran-3(2H)4 -piperidin]-5-yl]-3-(3,5- dichlorophenyl)-2-propenamideAmong the most preferred compounds of this invention are the following compounds: N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide hydrochloride;
N-[3-[2-(2,2,6,6-Tetramethylpiperidin-l-yl)ethoxy]-4-methoxy- phenyl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[3-[2-(4-Hydroxy-2,2,6,6-tetramethylpiperidin-l-yl)ethoxy]- 4-methoxyphenyl]-3-(3,4-dichlorophenyl)-2-propenamide; and N-[l'-(l-Methylethyl)spiro[benzofuran-3(2H)4'-piperidin]-5-yl]-3-(3,5- dichlorophenyl)-2-propenamide.
Among compounds excluded from this invention are the following compounds:
N-[4-Methoxy-3-[(2S)-(l-phenylmethyl-2- pyrrolidinyl)methoxy]phenyl]-3-(3,4-dichlorophenyl)-2-propenamide-;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- methylenedioxyphenyl)-2-propenamide; N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3- (3,4-methylenedioxyphenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(4- chlorophenyl)-2-propenamide; N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3- pyridinyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3- pyridinyl)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3- pyridinyl)-2-propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(3- pyridinyl)-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]-3-(3- pyridinyl)-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- pyridinyl)-2-propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3- ( 1 H-imidazol-4-yl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(3-pyridinyl)- 2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- pyridinyl)-2-propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(4- pyridinyl)-2-propenamide; N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]-3-(4- pyridinyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3- furanyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2-thienyl)- 2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(2-thienyl)-2- propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(2- thieny l)-2-propenamide ; N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]-3-(2- thienyl)-2-propenamide; and N- [3-[2- [Bis( 1 -methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-( 1 H- imidazol-4-yl)-2-propenamide.
Known compounds overlapping with the scope of the instant invention are as follows. A subgenus of formula (I) wherein: E is (a); B is meta to L;
B-CR1R2)a-NR3R4 is O-(CH2)3-N(CH3)2; L is CONH; R5, R6, R1 ', R2'5
R3', and R4' are hydrogen; and P1 is phenyl.
A further known subgenus of formula (I) is wherein:E is (a); B is para to L; B-(CR1R2)a-NR3R4 is S-(CH2)3-N(CH3)2; L is CONH; R5, R6, R1', R2', R3', and R4' are hydrogen; and P is phenyl.
Still a further known subgenus of formula (I) is wherein:E is (a); B-(CR1R2)a-NR R4 is ortho to L; B is CH2, NCH3, oxygen, S, or SO2; R1 and R2 are hydrogen or methyl; a is 0-4; R3 and R4 are independently hydrogen, C^alkyl, benzyl, or R3 and R4 taken together with the nitrogen to which they are attached form a pyrrolidinyl, piperidinyl, morpholino, and (4- methyl- 1 -piperazinyl), (4-phenyl- 1 -piperazinyl), [4-(2-methoxyphenyl)- 1 - piperazinyl], [4-(4-methoxyphenyl)-l -piperazinyl], or [(4-fluorophenyl)-l- piperazine] ring; NR3R4 is also present as a methochloride quaternary salt; R5 is hydrogen, methyl, acetyl, trifluoromethyl, nitro, methoxy, or chloro; L is CONR5'; R3' is hydrogen; R4' is hydrogen or C _4alkyl; R5' is hydrogen or
C^alkyl; P1 is phenyl or 2-thienyl; and R1' and R2' are independently hydrogen, methyl, trifluoromethyl, methoxy, fluoro, or chloro, all of which have been described in United States Patent 3,167,556, published January 26, 1965, United States Patent 3,201,401, published August 17, 1965, GB 1099829, published 17 January 1968, and Krapcho, et al., J. Med. Chem., 1969, 12, 164-6 as 5-HT inhibitors, and reported to have 5-HT inhibitory activity, and have been described in JP 05255291, published 5 October 1993, and reported to have calcium antagonist activity.
A compound of formula (I) wherein: E is (a); B is para to L; B-(CRlR )a NR3R4 is O-(CH2)2-N(Et)2; L is CONH; Rl ' is 5-nitro; R5, R6,
R2', R3', and R4' are hydrogen; and P1 is 2-furyl, has been described in JP 45006533, published 5 March 1970, and reported to have anti-cancer activity.
A compound of formula (I) wherein: E is (a); B is para to L; B-(CRiR2)a NR3R4 is O-CH2CH(OH)CH2-NH-tert-butyl; L is CONH; R6, Rl', R2', R3', R4', and R5' are hydrogen; R5 is 3-ethyl; and P1 is phenyl, has been described in ZA 6805360, published 19 February 1970, and reported to have «-adrenergic blocking activity.
A compound of formula (I) wherein: E is (a); B is para to L; B-(CRlR2)a NR3R4 is O-(CH2)2-(l-pyrrolidine); L is CONH; R2', R3', R4', and R^ are hydrogen; R5 is 3,5-dimethyl; Rl' is 2-methyl; and p is phenyl, have been described in DE 4036782, published 21 May 1992, as an antiarrhythmic. A subgenus of formula (I) wherein: E is (c); Q is ortho to L;
Q-(CR39R40)1-R4 is -(CH2)2-3-(2-piperidinyl); R47 is methyl or ethyl; R42 is hydrogen or methoxy; R43, Rl , R2' and R3' are hydrogen; L is CONR5'; R4' and R5' are independently hydrogen or methyl; pl is phenyl, have been described in United States Patent 3,931,195, published January 6, 1976, and United States Patent 4,000,143, published December 28, 1976, as antiserotonin agents
A subgenus of formula (I) wherein: E is (g); R71 is meta to L; R7 is (CQ-I alkyl- 1 -piperazine); R72 is 4-methoxy; Rl' is bromo, phenyl, or 4- pyridinyl; R73, R2', R3', and R4' are hydrogen; L is CONH; P1 is phenyl or 3- thienyl,have been described in international patent application WO 95/06044, published 2 March 1995, as 5-HT1D receptor antagonists.
Formulation of Pharmaceutical Compositions
The pharmaceutically effective compounds of this invention (and the pharmaceutically acceptable salts thereof) are administered in conventional dosage forms prepared by combining a compound of formula (I) ("active ingredient") in an amount sufficient to treat asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic diseases, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, COPD, and HIV infection, with standard pharmaceutical carriers or diluents according to conventional procedures well known in the art. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax. A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1000 mg. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
The active ingredient may also be administered topically to a mammal in need of treatment or prophylaxis of CCR5 mediated disease states. The amount of active ingredient required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the disease state being treated and the mammal undergoing treatment, and is ultimately at the discretion of the physician. A suitable dose of an active ingredient is 1.5 mg to 500 mg for topical administration, the most preferred dosage being 1 mg to 100 mg, for example 5 to 25 mg administered two or three times daily.
By topical administration is meant non-systemic administration and includes the application of the active ingredient externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream. By systemic administration is meant oral, intravenous, intraperitoneal and intramuscular administration.
While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e.g. from 1 % to 2% by weight of the formulation although it may comprise as much as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1% to 1% w/w of the formulation.
The topical formulations of the present invention, both for veterinary and for human medical use, comprise an active ingredient together with one or more acceptable carrier(s) therefor and optionally any other therapeutic ingredient(s). The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous or alcoholic solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of
« bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
The active ingredient may also be administered by inhalation. By "inhalation" is meant intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques. The daily dosage amount of the active ingredient administered by inhalation is from about 0.1 mg to about 100 mg per day, preferably about 1 mg to about 10 mg per day.
In one aspect, this invention relates to a method of treating asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic diseases, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, COPD, and HIV infection, all in mammals, preferably humans, which comprises administering to such mammal an effective amount of a CCR5 receptor modulator, in particular, a compound as depicted in formula (I).
By the term "treating" is meant either prophylactic or therapeutic therapy. Such formula (I) compound can be administered to such mammal in a conventional dosage form prepared by combining the formula (I) compound with a conventional pharmaceutically acceptable carrier or diluent according to known techniques. It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The formula (I) compound is administered to a mammal in need of treatment for CCR5-mediated diseases in an amount sufficient to decrease symptoms associated with these diseases. The route of administration may be oral or parenteral.
The term parenteral as used herein includes intravenous, intramuscular, subcutaneous, intra-rectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. The daily parenteral dosage regimen will preferably be from about 30 mg to about 300 mg per day of active ingredient. The daily oral dosage regimen will preferably be from about 100 mg to about 2000 mg per day of active ingredient. It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a formula (I) compound will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular mammal being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the formula (I) compound given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
Methods of Preparation Compounds of formula (I) are prepared by condensing suitably substituted 3- aryl or heteroaryl-2-propenoic acids and suitably substituted anilines, which are commercially available or synthesized by methods known to the art from commercially available starting materials, using methods known to the art. For example, suitably substituted 3-aryl or heteroaryl-2-propenoic acids are treated with a suitable reagent, such as thionyl chloride, at a suitable temperature, such as at reflux, to afford 3-aryl or heteroaryl-2-propenoyl chlorides, and the 3-aryl or heteroaryl-2-propenoyl chlorides are condensed with suitably substituted anilines in the presence of a suitable base, such as diisopropylethylamine, in a suitable solvent, such as dichloromethane, to give compounds of formula (I). Many additional methods for converting a carboxylic acid to an amide are known, and can be found in standard reference books, such as "Compendium of Organic Synthetic Methods", Vol. I- VI (published by Wiley-Interscience).
Compounds of this invention were also prepared using solid-phase chemistry as described in Scheme 1 and using the general method described in international patent application WO 99/01127, published 14 January 1999. Appropriately substituted 3- [2-(alkylamino)ethoxy] anilines 1-2, such as 3-[2- (diisopropylamino)ethoxy]-4-methoxyaniline, synthesized from commercially available 2-methoxy-5-nitrophenol, 1-1, according to the procedures described in WO 99/01127, is attached to a polymer support such as Merrifield resin-bound aldehyde 1-3, following the general protocol of Boojamra et al., (J. Org. Chem., 1995, 60, 5742-3) by reductive amination employing a suitable reducing agent, such as sodium triacetoxyborohydride, in a suitable solvent, such as dimethylformamide containing 1% acetic acid, to give 1-4. The resin-bound aniline 1-4 is acylated with a commercially available or synthetically accessible 3-aryl- or heteroaryl-2-propenoic acid 1-5, for example, 3-(3,4-dichlorophenyl)-2-propenoic acid, using, for example, N-bromosuccinimide and triphenylphosphine in dichloromethane, or in dichloromethane in combination with dimethylformamide, in the presence of an organic base such as pyridine to afford 1-6. For example, 1-4 is treated with a tenfold excess of an equimolar mixture of a 3-aryl- or heteroaryl-2-propenoic acid, triphenylphosphine and N-bromosuccinimide, in a suitable solvent, such as dichloromethane, after which a ten-fold excess of a suitable base, such as pyridine, is added, and the mixture is gently agitated for a suitable time, for example, forty-eight hours, to afford the resin-bound amide 1-6. Optionally, dimethylformamide may be added to the resulting mixture to increase the solubility of the 3-aryl- or heteroaryl-2- propenoic acid. Alternatively, 1-5 is converted to the acid chloride, for example by heating with thionyl chloride, and the acid chloride is condensed with 1-4 to afford I- 6. Treatment of 1-6 with a suitable acid in a suitable solvent, such as trifluoroacetic acid:dichloromethane:water (50:48:2) gives 3-aryl- or heteroaryl-2-propenamides 1-7 which are compounds of formula (I).
Scheme I:
Figure imgf000037_0001
(a) C1(CH2)2NR3R4, K CO3, CH3COCH3; (b) H2, 5% Pd/C, MeOH; (c) Merrifield resin bound aldehyde (3), NaBH(OAc)3, 1% HOAc/DMF; (d) 3-aryl- or heteroaryl- 2-propenoic acid, N-bromosuccinimide, Ph3P, pyridine, CH2CI2; (e) TFA, CH2CI2, H2O
The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. In the Examples, mass spectra were performed upon a VG Zab mass spectrometer using fast atom bombardment, unless otherwise indicated.
EXAMPLES
Preparation 1 Preparation of 4-Methoxy-3-[2-(2.2,6,6-tetramethylpiperidin-l- vDethoxy] aniline a) 4-methoxy- 1 -nitro-3-[2-(2,2,6,6-tetramethylpiperidin- 1 - yl)ethoxy]benzene A solution of 3-(2-bromoethoxy)-4-methoxy-l -nitrobenzene (Mutai et al., Tetrahedron, 1984, 40, 755) (3 g, 11 mmol) and 2,2,6,6- tetramethylpiperidine (23 g, 163 mmol) in dimethylformamide (60 mL) containing sodium iodide (1.65 g, 11 mmol) and potassium carbonate (2.4 g,
17 mmol) was stirred and heated to 110°C for 16 h. The mixture was cooled, diluted with dichloromethane to 350 mL, filtered, and the filtrate was concentrated in vacuo. The residue was partitioned between ethyl acetate (350 mL) and water (40 mL), the organic phase was washed with water (3 x 40 mL), dried (Na2SO4), concentrated in vacuo, and the residue was purified by flash chromatography (silica gel, dichloromethane followed by 2% methanol/dichloromethane-0.1 % ammonia). Fractions containing the title compound were combined, concentrated in vacuo, and the residue was purified by flash chromatography (silica gel, 50% ethyl acetate/hexane) to give the title compound. MS(ES) m/e 337 [M+H]+. b) 4-methoxy-3-[2-(2,2,6,6-tetramethylpiperidin- 1 -yl)ethoxy]aniline A mixture of the compound of Preparation 1(a) (0.57 g, 1.7 mmol), 5% palladium-on-carbon (0.40 g), and methanol (100 mL) was shaken in a hydrogen atmosphere (50 psi) for 3 h, degassed, filtered, and the filtrate was concentrated in vacuo to give the title compound. MS(ES) m/e 307 [M+H]+.
Preparation 2 Preparation of 4-Methoxy-3-[2-(4-hydroxy-2,2,6,6-tetramethylpiperidin-l- vDethoxy] aniline Following the procedure of Preparation l(a)-(b), except substituting 4-hydroxy-2,2,6,6-tetramethylpiperidine for 2,2,6,6- tetramethylpiperdine, gave the title compound.
Preparation 3 Preparation of 6-Amino-4-r2-[bis(l-methylethyl)amino]ethyl]-2H-l,4- benzoxazin-3 (4H)-one a) 4-[2-[bis(l-methylethyl)amino]ethyl]-6-nitro-2H-l,4-benzoxazin- 3(4H)-one
Sodium hydride (0.97 g of 60% dispersion in mineral oil, 24 mmol) was added portionwise to a suspension of 6-nitro-2H- 1 ,4-benzoxazine-3(4H)- one (J. Med. Chem. 1989, 32, 1627-1630)(4.3 g, 22 mmol) in tetrahydrofuran (100 mL) at RT resulting in a yellow heterogeneous mixture. 2- (Diisopropylamino)ethyl chloride hydrochloride was dissolved in water (80 mL) and then sodium carbonate was added until the solution was saturated.
*
The free amine was extracted with toluene (2 x 35 mL) and the toluene extracts were dried (MgSO4) and added dropwise to the above sodium salt. The resultant mixture was heated at reflux for 4 h, cooled, quenched with water (100 mL), and extracted with ethyl acetate (2 x 100 mL). The organic layers were combined, washed with brine, dried (MgSO4), and concentrated in vacuo. The crude product was triturated with hexanes to give 4.4 g (62 %) of the title compound as an off-white powder. MS(ES) m/e 322.1 [M+H]+. b) 6-amino-4- [2- [bis( 1 -methylethyl)amino]ethyl]-2H- 1 ,4-benzoxazin-
3(4H)-one
5% Palladium-on-carbon (0.8 g) was added to a solution of the compound of Preparation 3(a) (1.0 g, 3.1 mmol) and ethanol (25 mL). The resultant mixture was hydrogenated at 50 psi for 1 h. The mixture was then filtered through a pad of Celite® and concentrated in vacuo to afford 0.55 g (61%) of title compound as a white crystalline solid. MS(ES) m/e 292.1 [M+H]+.
Preparation 4 Preparation of 6-Amino-2,3-dihydro-N,N-bis( 1 -methylethyl)-4H- 1 A- benzoxazine-4-ethan amine a) 2,3-dihydro-N,N-[bis(l-methylethyl)-6-nitro-4H-l,4-benzoxazine-4- ethanamine
Boron trifluoride etherate (3.2 mL, 3.5 g, 25 mmol) was added slowly to a suspension of sodium borohydride (0.71 g, 14 mmol) in tetrahydrofuran (45 mL). The heterogeneous mixture was stirred at RT for 1 h, treated with a solution of the compound of Preparation 3(a) (2.0 g, 6.2 mmol) in tetrahydrofuran (30 mL), and the mixture heated at reflux for 2.5 h. The mixture was cooled to RT, excess reagent was quenched with saturated sodium bicarbonate, and the mixture was concentrated in vacuo. The residue was dissolved in ethanol (20 mL) and 3N hydrochloric acid (20 mL), and heated at reflux for 1 h. The mixture was made basic with 10% sodium carbonate and extracted with ethyl acetate (2 x 100 mL). The organic layers were combined, washed with brine, dried (MgSO4), and concentrated to give the title compound as a yellow oil (1.7 g, 89%). MS(ES) m e 308.1 [M+H]+. b) 6-amino-2,3-dihydro-N,N-bis( 1 -methylethyl)-4H- 1 ,4-benzoxazine-
4-ethanamine Following the procedure of Preparation 3(b), except substituting the compound of Preparation 4(a) for the compound of Preparation 3(a), gave the title compound.
Preparation 5 Preparation of 5-A ino-3-[2-[Bis(l-methylethyl)amino]ethyl1-2(3H)- benzoxazolone Following the procedure of Preparation 3(a)-(b), except substituting 5-nitro-2(3H)-benzoxazolone (WO 95/32967) for 6-nitro-2H-l,4- benzoxazin-3(4H)-one, gave the title compound.
Preparation 6 Preparation of 7- Anxino-3,4-dihvdro-N,N-bis(l -methylethyl)- 1(2H> quinolineethan amine a) 3 ,4-dihydro-N,N-bis( 1 -methylethyl)-7-nitro- 1 (2H)- quinolineethanamine
Sodium carbonate (2.9 g, 27 mmol) was added to a mixture of 7-nitro- 1,2,3,4-tetrahydroquinoline (United States Patent 5696133) (1.2 g, 6.7 mmol), 2-(diisopropylamino)ethyl chloride hydrochloride (4.0 g, 20 mmol) and ethanol (25 mL). The mixture was heated at reflux for 3 h, filtered, and concentrated in vacuo. The crude product was purified by chromatography (silica gel, dichloromethane followed by 5% methanol/dichloromethane) to afford 1.4 g (68%) of the title compound as a yellow oil. MS(ES) m/e 306.1 [M+H]+. b) 7-amino-3 ,4-dihydro-N,N-bis( 1 -methylethyl)- 1 (2H)- quinolineethanamine
Following the procedure of Preparation 3(b) except substituting the compound of Preparation 6(a) for the compound of Preparation 3(a), gave the title compound.
Preparation 7 Preparation of 6-Amino-2,3-dihydro-N,N-bis( 1 -methylethyl)- lH-indole- 1 - ethanamine Following the procedure of Preparation 6(a)-(b), except substituting 2,3-dihydro-6-nitro-lH-indole for 7-nitro- 1,2,3,4- tetrahydroquinoline, gave the title compound.
Preparation 8 Preparation of N-[ -(l-Methylethyl)spiro[benzofuran-3(2H),4'-piperidin]-5- amine a) 5- and 7-nitrospiro[benzofuran-3(2H),4'-piperidine]
A solution of l'-methyl-5- and 7-nitrospiro[benzofuran-3(2H),4'- piperidine] (WO 96/11934) (3 g, 12 mmol) and diisopropylethylamine (2.5 g, 19 mmol) in 1 ,2-dichloroethane (80 mL) was treated with 1-chloroethyl chloroformate (2.3 g, 16 mmol) at RT, stirred for 1 h, and heated to reflux for
20 min. The mixture was cooled, concentrated in vacuo, and the residue was dissolved in methanol, heated to reflux for 2 h, concentrated in vacuo, and the residue was partitioned between dichloromethane (250 mL) and 5% sodium bicarbonate (50 mL). The organic phase was washed with 5% sodium bicarbonate (50 mL) and the combined aqueous phase was extracted with dichloromethane (2 X 50 mL). The combined organic phase was dried (Na2SO4) and concentrated to afford the title compound (2. 65 g). b) l'-(tert-butoxycarbonyl)-5-nitrospiro[benzofuran-3(2H),4 - piperidine]
A solution of the compound of Preparation 8(a)(2.65 g, 1.13 mmol) in tetrahydrofuran (300 mL) was treated with di-tert-butyl dicarbonate (2.6 g, 12 mmol) and stirred at RT for 16 h. The mixture was concentrated in vacuo and the residue was crystallized from methanol to afford the title compound (2.1 g). c) 5-nitrospiro[benzofuran-3(2H),4 '-piperidine]
A solution of the compound of Preparation 8(b)(2.1 g, 6.3 mmol) in dichloromethane (50 mL) and trifluoroacetic acid (10 mL) was kept at RT for 5 h, concentrated in vacuo, and the residue was partitioned between dichloromethane (300 mL) and 5% sodium bicarbonate. The organic phase was washed with 5% sodium bicarbonate and the combined aqueous washes were extracted with dichloromethane. The combined organic phase was dried (Na2SO4) and concentrated in vacuo to give the title compound (1.45 g). MS(ES) m/e 235.1 [+H]+. d) l'-(l-methylethyl)-5-nitrospiro[benzofuran-3(2H),4'-piperidine] A mixture of the compound of Preparation 8(c) (1.45 g, 6.2 mmol), powdered potassium carbonate (0.86 g, 6.2 mmol) and dimethylformamide (50 mL) containing 2-iodopropane (1.1 g, 6.4 mmol) was stirred and heated to 50°C for 4 h, treated with 2-iodopropane (0.17 g, 1 mmol) at 50°C for 90 min, and treated with 2-iodopropane (0.1 g, 1 mmol) at 50°C for 2 h. The mixture was concentrated in vacuo and the residue was partitioned between ethyl acetate (200 mL) and water (20 mL). The organic phase was washed, dried (MgSO4), concentrated in vacuo, and the residue was chromatographed (silica gel, 5% methanol dichloromethane) to give the title compound (0.85 g). e) N-[ 1 '-( 1 -methylethyl)spiro[benzofuran-3(2H),4'-piperidin]-5-amine A solution of the compound of Preparation 8(d) (0.78 g, 2.8 mmol) in methanol (250 mL) containing 10% palladium-on-carbon (0.375 g) was shaken in a hydrogen atmosphere (40 psi) for 40 min, filtered, and concentrated in vacuo to afford the title compound (0.6 g). Preparation 9
Preparation of 3-[2-Acetoxy-3-(diisopropylamino)propoxy1-4-methoxyaniline a) 4-methoxy-3-(oxiranyl)methoxy- 1 -nitrobenzene
A solution of 3-chloroperbenzoic acid (11 mmol) in dichloromethane
(50 mL) was added dropwise to a solution of l-methoxy-4-nitro-2-(2- propenyloxy)benzene (Molina et al., Tetrahedron Lett., 1992, 33, 2387-90) (2 g, 9.6 mmol) in dichloromethane (50 mL) and stirred at RT for 6 d. The mixture was washed with 5% sodium sulfite (35 mL) and then with 5% sodium bicarbonate. The organic phase was dried (MgSO4), concentrated in vacuo, and the residue was recrystalhzed from ethanol (50 mL) to give the title compound (1 g) as a yellow solid. b) 3 - [3 -diisopropylamino-2- (hydroxy )propoxy] -4-methoxy- 1 - nitrobenzene
A mixture of the compound of Preparation 9(a)(l g, 4.4 mmol) and diisopropylamine (5.7 g, 44 mmol) in ethanol (50 mL) was heated to 50°C for 2 h, cooled, kept at RT for 16 h, heated to 50°C for 6 h, cooled, and concentrated in vacuo to give the title compound as a yellow oil (1.4 g). MS(ES) m e 327.0 [M+H]+. c) 3-[2-acetoxy-3-(diisopropylamino)propoxy]-4-methoxy-l- nitrobenzene A solution of the compound of Preparation 9(b)( 1.4 g, 4.2 mmol) and diisopropylethylamine (0.57 g, 4.4 mmol) in dichloromethane (50 mL) was treated with acetyl chloride (0.35 g, 4.4 mmol) at RT and stirred for 16 h. The mixture was washed with 5% sodium carbonate, dried (Na2SO4), and concentrated in vacuo. The residue was chromatographed (silica gel, 3% methanol/dichloromethane) and fractions containing the title compound were combined, concentrated in vacuo and rechromatographed (silica gel, 1 % methanol/dichloromethane) to give the title compound (0.9 g). MS(ES) m e 369.0 [M+H]+. d) 3-[2-acetoxy-3-(diisopropylamino)proxy]-4-methoxyaniline A solution of the compound of Preparation 9(c)(0.27 g, 0.73 mmol) in methanol(50 mL) containing 10% palladium-on-carbon (0.1 g) was shaken in a hydrogen atmosphere (40 psi) at RT for 1 h. The mixture was filtered and concentrated in vacuo to give the title compound. MS(ES) m/e 339.0 [M+H]+.
Preparation 10 Preparation of (S)-2-[(2-methoxy-5-nitrophenoxy)methyl]pyrrolidine (S)-l-(tert-Butoxycarbonyl)-2-pyrrolidinemethanol (28.2 g, 0.14 mol) and 2- methoxy-5-nitrophenol (24.1 g, 0.14 mol) were stirred in anhydrous tetrahydrofuran (1.5 L). Triphenylphosphine ( 36.7 g, 0.14 mol) was added and the mixture was stirred, cooled in an ice bath to 10°C, and diethyl azodicarboxylate ( 24.4 g, 0.14 mol) was added over 30 min while the reaction temperature was maintained below 25°C. The mixture was then allowed to stand at RT for 16 h, concentrated in vacuo, the residue dissolved in dichloromethane
(1500 ml), and washed with 10% aqueous sodium hydroxide and water. The organic phase was dried (Na2SO4), filtered, and the filtrate was treated with trifluoroacetic acid (100 mL) and allowed to stand at RT for 16 h. The mixture was concentrated in vacuo and the residue was dissolved in diethyl ether (1.5 L). The ether solution was extracted thoroughly with 10% hydrochloric acid, and the aqueous phase was washed with ether and then basified with 40% aqueous sodium hydroxide. The product was extracted into ether, and the ether solution was washed with water, dried (Na2SO4), and concentrated in vacuo to afford the title compound
(24.48g, 70% yield) as a yellow solid. MS(ES) m e 253 [M+H]+.
Example 1 Preparation of N-[3-r2-[Bis( 1 -methylethyl)aminolethoxy1-4-methoxyphenyl]- 3-(3,4-dichlorophenyl)-2-propenamide
A solution of 3,4-dichlorocinnamoyl chloride (0.2 g, 0.85 mmol), prepared from 3,4-dichlorocinnamic acid and thionyl chloride, in dichloromethane (10 mL) was added in one portion to a solution of 3-[2- (diisopropylamino)ethoxy]-4-methoxyaniline (WO 95/15954)(0.23 g, 0.85 mmol) and diisopropylethylamine (0.11 g, 0.85 mmol) in dichloromethane (10 mL), and the mixture was stirred at RT for 16 h. The mixture was diluted with dichloromethane (50 mL), washed with 5% aqueous sodium carbonate, dried (Na2SO4), concentrated in vacuo, and the residue was purified by flash chromatography (silica gel, 5% methanol/dichloromethane-0.1% ammonia) to afford the title compound (250 mg, 63%). MS(ES) m/e 465.3 [M+H]+.
Examples 2-3 Preparation of N-[3-[2-fBis( 1 -methylethyl)amino]ethoxy1-4-methoxyphenyl]- 3-phenyl-2-propenamide and N-[3-[2-[Bis(l-methylethyl)amino]ethoxy1-4- methoxyphenyl]-3-(2-naphthalenyl)-2-propenamide Following the procedure of Example 1 , except substituting cinnamic acid and 3-(2-naphthalenyl)-2-propenoic acid for 3,4-dichlorocinnamic acid, gave the title compounds:
N- [3 - [2- [bis( 1 -methylethyl)amino] ethoxy ] -4-methoxyphenyl] -3 - phenylpropenamide: MS(ES) m/e 397.3 [M+H]+; and
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide: MS(ES) m/e 446.9 [M+H]+.
Example 4
Preparation of (E)-N-[3-[2-rBis(l-methylethyl)amino1ethoxy]-4- methoxyphenyl1-3-[4-chloro-3-(trifluoromethyl)phenyl1-2-propenamide
Following the procedure of Example 1, except substituting 4-chloro-3-
(trifluoromethyl)cinnamic acid for 3,4-dichlorocinnamic acid and substituting triethylamine for diisopropylethylamine, gave the title compound. MS(ES) m/e 498.7, 500.7 [M+H]+. Example 5
Preparation of (E)-N-[3-[2-rBis(l-methylethyl)amino]ethoxy1-4- methoxyphenyl1-3-(3-chlorophenyl)-2-propenamide
A solution of 3-chlorocinnamic acid (0.18 g, 1 mmol), 3-[2-
(diisopropylamino)ethoxy]-4-methoxyaniline (WO 95/15954)(0.27 g, 1 mmol), and BOP reagent (0.44 g, 1 mmol) in acetonitrile (20 mL) was treated with triethylamine (0.22 g, 2.2 mmol) and stirred at RT for 16 h. The mixture was treated with brine (50 mL) and extracted with ethyl acetate. The combined organic phase was washed with 5% sodium carbonate and with brine, dried (MgSO4) and concentrated in vacuo. The residue was chromatographed (silica gel, 5% methanol/dichloromethane) to give the title compound (0.2 g). MS(ES) m/e 431.1 [M+H]+.
Examples 6-12 Following the procedure of Example 5, except substituting 3-(5- indolyl)-2-propenoic acid, 3-(6-indolyl)-2-propenoic acid, •,•- dimethylcinnamic acid, •-(acetylamino)-3,4-dichlorocinnamic acid, 3-(5,6,7,8- tetrahydronaphth-2-yl)-2-propenoic acid, 4-chloro-3-methylcinnamic acid, and
3,4-dichloro-«-methylcinnamic acid for 3-chlorocinnamic acid, gave the following compounds:
(E)-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(5- indolyl)-2-propenamide: MS(ES) m/e 435.9 [M+H]+;
(E)-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl)-3-(6- indolyl)-2-propenamide: MS(ES) m/e 436.1 [M+H]+; (E)-»«»-dimethyl-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4- methoxyphenyl]-3-phenyl-2-propenamide: MS(ES) m/e 425.0 [M+H]+;
(Z)-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl)-«-
(acetylamino)-3-(3,4-dichlorophenyl)-2-propenamide: MS(ES) m/e 521.7, 523.6 [M+H]+;
(E)-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(5,6,7,8- tetrahydronaphth-2-yl)-2-propenamide trifluoroacetate salt: MS(ES) m/e
450.5 [M+H]+;
(E)-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]- 3-(4-chloro-3-methylphenyl)-2-propenamide: MS(ES) m e 444.8, 446.8
[M+H]+; and
(E)-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-»-methyl-2-proρenamide: MS(ES) m/e 478.7, 480.7 [M+H]+.
Examples 13-15 Preparation of N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxypheny1-
3-(4-fluorophenyl)-2-propenamide; (E)-N-r3-r2-rBis(l- methylethyl)amino1ethoxy1-4-methoxyphenyl]-3-(3,5-dichlorophenyl)-2- propenamide trifluoroacetate; and (E)-N-[3-[2-[Bis(l- methylethyl)amino1ethoxy1-4-methoxyphenyl1-3-r4-(trifluoromethyl)phenyl]- 2-propenamide
Following the procedure of Example 5, except substituting 4- fluorocinnamic acid, 3,5-dichlorocinnamic acid, and 4-
(trifluoromethyl)cinnamic acid for 3-chlorocinnamic acid, gave the title compounds: N-[3-[2-[bis( 1 -methylethyl)amino]ethoxy]-4-methoxypheny]-3-(4- fluorophenyl)-2-propenamide: MS(ES) m/e 414.9 [M+H]+;
(E)-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,5- dichlorophenyl)-2-propenamide trifluoroacetate: MS(ES) m/e 466.8 [M+H]+; and (E)-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-[(4- trifluoromethyl)phenyl]-2-propenamide: MS(ES) m/e 464.8 [M+H]+.
Example 16
Preparation of N-[3-[2-(2,2,6,6-tetramethylpiperidin- 1 -yl)ethoxy1-4-methoxy- phenyl]-3-(3,4-dichlorophenyl)-2-propenamide Following the procedure of Example 1 , except substituting the compound of Preparation 1(b) for 3-[2-(diisopropylamino)ethoxy]-4- methoxyaniline, gave the title compound. MS(ES) m/e 505.0 [M+H]+. Example 17
Preparation of N-[3-[2-(4-Hydroxy-2,2.6,6-tetramethylpiperidin-l-yl)ethoxy1-
4-methoxyphenyl]-3-(3,4-dichlorophenyl)-2-propenamide
Following the procedure of Example 16, except substituting the compound of Preparation 2 for the compound of Preparation 1(b), gave the title compound. MS(ES) m/e 521.1, 523.1 [M+H]+.
Examples 18-22
Preparation of N-[4-[2-[Bis(l-methylethyl)amino1ethyl1-3,4-dihvdro-3-oxo-
2H-l,4-benzoxazin-6-yl]-3-(3,4-dichlorophenyl)-2-propenamide; N-[4-f2- rBis(l-methylethyl)amino1ethyl1-3.4-dihvdro-2H-1.4-benzoxazin-6-yl]-3-(3.4- dichlorophenyhl-2-propenamide; N-[3-r2-[Bis(l-methylethyl)amino]ethyll-2- oxo-(3H)-benzoxazol-5-yn-3-(3,4-dichlorophenyl)-2-propenamide; N-[2,3-
Dihvdro-l-[2-[bis(l-methylethyl)amino1ethyll-lH-indol-6-yl]-3-(3.4- dichlorophenyl)-2-propenamide; and N-[l-[2-[Bis(l- methylethyl)amino1ethyl1-l,2,3,4-tetrahydroquinol-7-yl1-3-(3,4- dichlorophenyl)-2-propenamide
Following the procedure of Example 1, except substituting the compounds of Preparations 3-7 for 3-[2-(diisopropylamino)ethoxy]-4- methoxyaniline, gave the title compounds: N-[4-[2-[bis(l-methylethyl)amino]ethyl]-3,4-dihydro-3-oxo-2H-l,4- benzoxazin-6-yl]-3-(3,4-dichlorophenyl)-2-propenamide: MS(ES) m/e 490.0,
491.9 [M+H]+;
N- [4- [2- [bis( 1 -methylethyl)amino]ethyl] -3 ,4-dihydro-2H- 1 ,4-benzoxazin-6- yl]-3-(3,4-dichlorophenyhl-2-propenamide: MS(ES) m/e 476.0, 477.9 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethyl]-2-oxo-(3H)-benzoxazol-5-yl]-3-(3,4- dichlorophenyl)-2-propenamide: MS(ES) m/e 475.9, 477.9 [M+H]+;
N-[2,3-dihydro-l-[2-[bis(l-methylethyl)amino]ethyl]-lH-indol-6-yl]-3-(3,4- dichlorophenyl)-2-propenamide: MS(ES) m/e 459.9, 461.9 [M+H]+; and N-[l-[2-[bis(l-methylethyl)amino]ethyl]-l,2,3,4-tetrahydroquinol-7-yl]-3-
(3,4-dichlorophenyl)-2-propenamide: MS(ES) m/e 474.1, 476.1 [M+H]+.
Example 23
Preparation of N-(l '-Methylspiro[benzofuran-3(2H),4'-piperidin]-5-yl)-3-(3.4- dichlorophenyl)-2-propenamide Following the procedure of Example 1 , except substituting l'-methyl-5-nitrospiro[benzofuran-3(2H),4 -piperidine]
(WO 96/11934) for 3-[2-(diisopropylamino)ethoxy]-4-methoxyaniline, gave the title compound: MS(ES) m e 418.4 [M+H]+. Example 24
Preparation of N-(Spiro[benzofuran-3(2H),4'-piperidin]-5-yl)-3-(3,4- „, dichlorophenyl)-2-propenamide
A solution of the compound of Example 23(0.28 g, 0.67 mmol) and diisopropylethylamine (0.13 g, 1 mmol) in 1,2-dichloroethane (15 mL) was treated with 1-chloroethyl chloroformate (0.12 g, 0.86 mmol), stirred for 1 h at RT, and heated to reflux for 20 min. The mixture was cooled, concentrated in vacuo, and the residue was dissolved in methanol (25 mL), heated to reflux for 2 h, and stirred at RT for 16 h. The mixture was cooled, concentrated in vacuo, and the residue was dissolved in dichloromethane (100 mL) and washed with 5% sodium carbonate. The organic phase was dried (MgSO4), concentrated in vacuo, treated with dichloromethane, and concentrated in vacuo several times to give the title compound. MS(ES) m/e 404 [M+H]+.
Example 25 Preparation of N-[ 1 '-( 1 -Methylethyl)spiro[benzofuran-3(2H)4'-piperidin]-5- yl1-3-(3.4-dichlorophenyl)-2-propenamide
A solution of the compound of Example 24 (0.15 g, 0.37 mmol) in dimethylformamide containing 2-iodopropane (65 mg, 0.38 mmol) and powdered potassium carbonate (56 mg, 0.4 mmol) was heated to 50°C for 15 h, cooled, and concentrated in vacuo. The residue was partitioned between ethyl acetate (120 mL) and water (10 mL), and the organic phase was washed with water and with brine, dried (Mg SO4), and concentrated in vacuo. The residue was chromatographed (silica gel, 5% methanol/dichloromethane) to give the title compound. MS(ES) m/e 446.9 [M+H]+. Example 26
Preparation of N-[ 1 '-( 1 -Methylethyl)spiro[benzofuran-3(2H)4 -piperidinl-5- yl1-3-(3,5-dichlorophenyl)-2-propenamide Following the procedure of Example 5, except substituting 3,5-dichlorocinnamic acid for 3- chlorocinnamic acid and the compound of Preparation 8(e) for 3- [2- (diisopropylamino)ethoxy]-4-methoxyaniline, gave the title compound. MS(ES) m/e 445.0 [M+H]+.
Example 27 Preparation of N-r3-[3-[Bis(l-methylethyl)amino1propyπ-4-methoxyphenvH- 3-(3,4-dichlorophenyl)-2-propenamide Following the procedure of Example 1, except substituting 3-[3-(diisopropylamino)propyl]-4-methoxyaniline (WO 99/01127) for 3-[2-(diisopropylamino)ethoxy]-4-methoxyaniline, gave the title compound. MS(ES) m/e 462.9 [M+H]+. Example 28
Preparation of N-[3-[3-[Bis(l-methylethyl)amino1propoxy1-4- ^ methoxyphenyll-3-(3,4-dichlorophenyl)-2-propenamide Following the procedure of Example 1, except substituting 3-[3- (diisopropylamino)propoxy]-4-methoxyaniline (WO 99/01127) for 3-[2- (diisopropylamino)ethoxy]-4-methoxyaniline, gave the title compound. MS(ES) m/e 480.7 [M+H]+.
Example 29 Preparation of N-[3-[2-Acetoxy-3-[bis(l-methylethyl)amino]propoxy1-4- methoxyphenyl]-3-(3,4-dichlorophenyl)-2-propenamide
Following the procedure of Example 1 , except substituting the compound of Preparation 9(d) for 3-[2-(diisopropylamino)ethoxy]-4- methoxyaniline, gave the title compound. MS(ES) m/e 538.9 [M+H]+.
Example 30 Preparation of N-[3-[3-[Bis(l-methylethyl)aminolpropyl]-4-methoxyphenvn- 3-(4-chlorophenyl)-2-propenamide a) [3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyaniline/(4- formyl-3,5-dimethoxy-phenoxy)-Merrifield resin adduct
A mixture of 4-formyl-3,5-dimethoxy-phenoxy-Merrifιeld resin (Boojamra et al., J. Org. Chem. 1995, 60, 5742-3), 3-[3-
(diisopropylamino)propyl]-4-methoxyaniline (WO 99/01127), and sodium triacetoxyborohydride in dimethylformamide containing 1 % acetic acid was shaken to afford the title adduct. b) N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- chlorophenyl)-2-propenamide/(4-formyl-3,5-dimethoxy-phenoxy)-Merrifield resin adduct
The resin of Example 30(a) was placed in an Irori MicroKan and treated with a ten-fold molar excess of an equimolar mixture of 4- chlorocinnamic acid, N-bromosuccinimide, and triphenylphosphine in dichloromethane, followed by addition of a ten-fold excess of pyridine. The mixture was gently agitated for 48 h after which the resin was washed three- times, sequentially with dimethylformamide, dichloromethane, and methanol to afford the title adduct. c) N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- chlorophenyl)-2-propenamide The resin of Example 30(b) was stirred in a mixture of trifluoroacetic acid: dichloromethane: water (50:48:2), filtered, and the filtrate concentrated in ^ vacuo to afford the title compound. MS(ES) m/e 429.0 [M+H]+.
Examples 31-62 Following the procedure of Example 30(a)-(c), except substituting 3-
[2-(diisopropylamino)ethoxy]-4-methoxyaniline (WO 95/15954), 3-[2-(N- cyclohexyl-N-isopropylarnino)ethoxy]-4-methoxyaniline (WO 99/01127), and 3-[2-(cis-2,6-dimethylpiperidin- 1 -yl)ethoxy]-4-methoxyaniline (WO 99/01127) for 3-[3-(diisopropylamino)propyl]-4-methoxyaniline, and using 3- chlorocinnamic acid, 3,4-(methylenedioxy)cinnamic acid, 3,4- difluorocinnamic acid, and 3-(2-naphthalenyl)-2-propenoic acid, in addition to 4-chlorocinnamic acid, gave the title compounds:
N- [3 - [2-(cis-2 ,6-dimethylpiperidin- 1 -y l)ethoxy ] -4-methoxyphenyl] -3 - (3-chlorophenyl)-2-propenamide: MS(ES) m/e 443.0 [M+H]+; N-[3-[2-(N-cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]-
3-(3-chlorophenyl)-2-propenamide: MS(ES) m/e 471.0 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- chlorophenyl)-2-propenamide: MS(ES) m/e 431.0[M+H]+;
N-[3-[2-(cis-2,6-dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3- (4-chlorophenyl)-2-propenamide: MS(ES) m/e 442.9[M+H]+;
N-[3-[2-(N-cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]- 3-(4-chlorophenyl)-2-propenamide: MS(ES) m/e 470.9 [M+H]+;
N-[3-[2-(N-cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]- 3-[(3,4-methylenedioxy)phenyl]-2-propenamide: MS(ES) m/e 481.0 [M+H]+; N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide: MS(ES) m/e 432.9 [M+H]+;
N-[3-[2-(cis-2,6-dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3- (3,4-difluorophenyl)-2-propenamide: MS(ES) m/e 444.9 [M+H]+;
N- [3 - [2- (N-cyclohexyl-N-isopropylamino)ethoxy ] -4-methoxyphenyl] - 3-(3,4-difluorophenyl)-2-propenamide: MS(ES) m/e 473.0 [M+H]+;
N-[3-[2-(N-cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]- 3-(2-naphthalenyl)-2-propenamide: MS(ES) m/e 487.4 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-[3- (trifluoromethyl)phenyl]-2-propenamide: MS(ES) m/e 465.2 [M+H]+; N-[3-[2-[bis( 1 -methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- chloroρhenyl)-2-propenamide: MS(ES) m/e 431.2 [M+H]+; N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,4- dichlorophenyl)-2-propenamide: MS(ES) m/e 465.2 [M+H]+; ^
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,6- dichlorophenyl)-2-propenamide: MS(ES) m e 465.2 [M+H]+; N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,5- difluorophenyl)-2-propenamide: MS(ES) m/e 433.2 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,5- difluorophenyl)-2-propenamide: MS(ES) m/e 433.2 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,4- difluorophenyl)-2-propenamide: MS(ES) m/e 433.2 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3- fluorophenyl)-2-propenamide: MS(ES) m/e 415.2 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- chloro-6-fluorophenyl)-2-propenamide: MS(ES) m/e 449.2 [M+H]+; N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- bromo-2-fluorophenyl)-2-propenamide: MS (ES) m/e 493.1 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- chloro-2-fluorophenyl)-2-propenamide: MS(ES) m/e 449.2 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- chloro-4-fluorophenyl)-2-propenamide: MS(ES) m/e 449.2 [M+H]+
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,6- difluorophenyl)-2-propenamide: MS(ES) m/e 433.2 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- bromophenyl)-2-propenamide: MS(ES) m/e 475.2 [M+H]+; N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- chloro-3-nitrophenyl)-2-propenamide: MS(ES) m/e 476.2 [M+H]+;
N- [3 - [2- [bis( 1 -methylethy l)amino] ethoxy] -4-methoxyphenyl] -3 - [4-( 1 - methylethyl)phenyl]-2-propenamide: MS(ES) m/e 439.3 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(5- bromo-2-methoxyphenyl)-2-ρropenamide: MS(ES) m/e 505.2 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-([l,l'- biphenyl]-4-yl)-2-propenamide: MS(ES) m/e 473.3 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3- bromo-4-fluorophenyl)-2-propenamide: MS (ES) m/e 493.1 [M+H]+; N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dimethylphenyl)-2-propenamide: MS(ES) m/e 425.3 [M+H]+; N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- cyanophenyl)-2-propenamide: MS(ES) m/e 422.2 [M+H]+; and %
N- [3 - [2- [bis( 1 -methylethyl) amino]ethoxy ] -4-methoxyphenyl] -2- fluoro-3-phenyl-2-propenamide: MS(ES) m/e 415.2 [M+H]+. Examples 63-90
Following the procedure of Example 30(b)-(c), except substituting 3,4- difluorocinnamic acid, 3,4-dichlorocinnamic acid, 3-chlorocinnamic acid, 3,4- (methylenedioxy)cinnamic acid, and 3-(2-naphthalenyl)-2-propenoic acid for 4-chlorocinnamic acid, gave the title compounds: N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide: MS(ES) m/e 431.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide: MS(ES) m/e 462.9 [M+H]+;
N-[3-[3-[bis(l -methylethy l)amino]propy 1] -4-methoxyphenyl] -3 -(3 - chlorophenyl)-2-propenamide: MS(ES) m/e 428.9[M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[(3,4- methylenedioxy)phenyl]-2-propenamide: MS(ES) m/e 438.9[M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide: MS(ES) m/e 445.4 [M+H]+; N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[4-
(trifluoromethyl)phenyl]-2-propenamide: MS(ES) m/e 463.3 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[3- (trifluoromethyl)phenyl]-2-propenamide: MS (ES) m/e 463.3 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2- chlorophenyl)-2-ρropenamide: MS(ES) m/e 429.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,4- dichlorophenyl)-2-propenamide: MS(ES) m/e 463.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,6- dichlorophenyl)-2-ρroρenamide: MS(ES) m/e 463.2 [M+H]+; N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,5- difluorophenyl)-2-propenamide: MS(ES) m/e 431.3 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,5- difluorophenyl)-2-propenamide: MS(ES) m/e 431.3 [M+H]+;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,4- difluorophenyl)-2-propenamide: MS(ES) m/e 431.3 [M+H]+;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3- fluorophenyl)-2-propenamide: MS(ES) m/e 413.3 [M+H]+; N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2- chloro-6-fluorophenyl)-2-proρenamide: MS(ES) m/e 447.2 [M+H]+;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- bromo-2-fluorophenyl)-2-propenamide: MS(ES) m/e 491.2 [M+H]+; N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- chloro-2-fluorophenyl)-2-propenamide: MS(ES) m/e 447.2 [M+H]+;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2- chloro-4-fluorophenyl)-2-ρropenamide: MS(ES) m/e 447.2 [M+H]+;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,6- difluorophenyl)-2-propenamide: MS(ES) m/e 431.3 [M+H]+;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- bromophenyl)-2-propenamide: MS(ES) m/e 473.2 [M+H]+;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- chloro-3-nitrophenyl)-2-propenamide: MS(ES) m/e 474.2 [M+H]+; N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[4-(l- methylethyl)phenyl]-2-propenamide: MS(ES) m/e 437.3 [M+H]+;
N-[3-[3-[Bis(l -methylethy l)amino]propyl] -4-methoxyphenyl] -3 -(5 - bromo-2-methoxyphenyl)-2-propenamide: MS(ES) m/e 503.2 [M+H]+;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3- bromo-4-fluorophenyl)-2-propenarnide: MS(ES) m/e 491.2 [M+H]+;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,5- dichlorophenyl)-2-propenamide: MS(ES) m/e 463.2 [M+H]+;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- dimethylphenyl)-2-propenamide: MS(ES) m/e 423.3 [M+H]+ N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- cyanophenyl)-2-propenamide: MS(ES) m/e 420.3 [M+H]+; and
N-[3-[3-[Bis( 1 -methylethyl)amino]propyl]-4-methoxyphenyl]-2- fluoro-3-phenyl-2-propenamide: MS(ES) m/e 413.3 [M+H]+.
Examples 91-117 Following the procedure of Example 30(a)-(c), except substituting 3-
[3-(diisopropylamino)propoxy]-4-methoxyaniline (WO 99.01127) for 3-[3- (diisopropylamino)propyl]-4-methoxyaniline and using 3-chlorocinnamic acid, 3,4-(methylenedioxy)cinnamic acid, 3,4-difluorocinnamic acid, and 3-(2- naphthalenyl)-2-propenoic acid, in addition to 4-chlorocinnamic acid, gave the title compounds:
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3- chlorophenyl)-2-propenamide: MS(ES) m e 444.9 [M+H]+; N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyρhenyl]-3-(4- chlorophenyl)-2-propenamide: MS(ES) m/e 444.9 [M+H]+; ^
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3- [(3,4-methylenedioxy)phenyl]-2-propenamide: MS(ES) m/e 454.9 [M+H]+; N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide: MS(ES) m/e 446.9 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide: MS(ES) m/e 461.6 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-[3- (trifluoromethyl)phenyl]-2-ρroρenamide: MS(ES) m/e 479.3 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- chlorophenyl)]-2-proρenamide: MS(ES) m/e 445.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,4- dichlorophenyl)]-2-propenamide: MS(ES) m/e 479.2 [M+H]+; N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,6- dichlorophenyl)]-2-propenamide: MS(ES) m/e 479.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,5- difluorophenyl)]-2-propenamide: MS(ES) m/e 447.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,5- difluorophenyl)]-2-propenamide: MS(ES) m e 447.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,4- difluorophenyl)]-2-propenamide(SB-383258): MS(ES) m/e 447.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3- fluorophenyl)]-2-propenamide: MS(ES) m/e 429.3 [M+H]+; N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- chloro-6-fluoroρhenyl)]-2-propenamide: MS(ES) m/e 463.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- bromo-2-fluorophenyl)]-2-propenamide: MS(ES) m/e 507.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- chloro-2-fluoroρhenyl)]-propenamide: MS(ES) m/e 463.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- chloro-4-fluorophenyl)-2-propenamide: MS(ES) m/e 463.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,6- difluorophenyl)]-2-proρenamide: MS(ES) m/e 447.2 [M+H]+; N-[3-[3-[bis(l -methylethy l)amino]propoxy] -4-methoxyphenyl] -3-(4- bromophenyl)]-2-propenamide: MS(ES) m/e 489.2 [M+H]+; N-[3-[3-[bis(l -methylethy l)amino]propoxy] -4-methoxyphenyl] -3- [4- (l-methylethyl)phenyl]-2-propenamide: MS(ES) m/e 453.3 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3- ([l,l'-biphenyl]-4-yl)-2-propenamide: MS(ES) m/e 487.3 [M+H]+; N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,3- dihydro-lH-inden-5-yl)-2-propenamide: MS(ES) m/e 451.3 [M+H]+;
N-[3- [3- [bis( 1 -methylethy l)amino]propoxy]-4-methoxyphenyl]-3-(3- bromo-4-fluoroρhenyl)]-2-propenamide: MS(ES) m/e 507.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,5- dichlorophenyl)]-2-propenamide: MS(ES) m/e 479.2 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,4- dimethylphenyl)-2-propenamide: MS(ES) m/e 439.3 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- cyanophenyl)] -2-propenamide: MS(ES) m/e 436.3 [M+H]+; and N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-2- fluoro-3-phenyl-2-propenamide: MS(ES) m/e 429.3 [M+H]+.
Examples 118-120 Following the procedure of Example 30(a)-(c), except substituting 3- [2-(diisopropylamino)ethoxy]-4-methylaniline (WO 9901127) for 3-[3- (diisopropylamino)propyl]-4-methoxyaniline and substituting 3,4- (methylenedioxy)cinnamic acid, 3,4-difluorocinnamic acid, and 3-(2- naphthalenyl)-2-propenoic acid for 4-chlorocinnamic acid, gave the title compounds:
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-[(3,4- methylenedioxy)ρhenyl]-2-propenamide: MS(ES) m/e 424.9 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(3,4- difluorophenyl)-2-propenamide: MS(ES) m/e 417.0 [M+H]+; and
N-[3-[2-[bis( 1 -methylethyl)amino]ethoxy]-4-methylphenyl]-3-(2- naphthalenyl)-2-proρenamide: MS(ES) m/e 431.0 [M+H]+. Examples 121-135
Following the procedure of Example 30(a)-(c), except using 3-[2- (diisopropylamino)ethoxy]-4-methoxyaniline (WO 95/15954), 3-[2- (diisopropylamino)ethoxy]-4-methylaniline (WO 99/01127), 3-[2-(N-cyclohexyl-N- isopropylamino)ethoxy]-4-methoxyaniline (WO 99/01127), and 3-[2-(cis-2,6- dimethylpiperidin-l-yl)ethoxy]-4-methoxy aniline (WO 99/01127) in addition to 3- [3-(diisopropylamino)propyl]-4-methoxyaniline, and substituting 3-(3-thienyl)-2- propenoic acid, 3-(4-pyridinyl)-2-propenoic acid, 3-(3-furanyl)-2-propenoic acid, and 3-(2-thienyl)-2-propenoic acid for 4-chlorocinnamic acid, and using , afforded the title compounds:
N-[3-[2-[bis(l -methylethy l)amino]ethoxy ] -4-methoxyphenyl] -3-(3 - thienyl)-2-propenamide: MS(ES) m/e 403.0 [M+H]+; N-[3-[3-[bis( 1 -methylethy l)amino]propyl]-4-methoxyphenyl]-3-(3-thienyl)-
2-propenamide: MS(ES) m/e 401.0 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3-thienyl)- 2-propenamide: MS(ES) m/e 417.0 [M+H]+;
N-[3-[2-(cis-2,6-dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(3- thienyl)-2-propenamide: MS(ES) m/e 415.0 [M+H]+;
N-[3-[2-(N-cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]-3-(3- thienyl)-2-propenamide: MS(ES) m/e 443.0 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(4-pyridinyl)- 2-propenamide: MS(ES) m/e 382.0 [M+H]+; N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- pyridinyl)-2-propenamide: MS(ES) m/e 412 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3-furanyl)- 2-propenamide: MS(ES) m/e 387.4 [M+H]+;
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(3-furanyl)-2- propenamide: MS(ES) m/e 371.0 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3-furanyl)- 2-propenamide: MS(ES) m/e 385.0 [M+H]+;
N-[3-[2-(cis-2,6-dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(3- furanyl)-2-propenamide: MS(ES) m/e 399.0 [M+H]+; N-[3-[2-(N-cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]-3-(3- furanyl)-2-propenamide: MS(ES) m/e 427.0 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2-thienyl)- 2-propenamide: MS(ES) m/e 401.0 [M+H]+;
N-[3-[3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2-thienyl)- 2-propenamide: MS(ES) m/e 417.0 [M+H]+; and
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2-furanyl)- 2-propenamide: MS(ES) m/e 387.1 [M+H]+.
Example 136 Preparation of N-[3-f2-[Bis( l-methylethyl)amino]ethoxy1-4-methoxyphenyll-3-(2- furanyl)-2-propenamide Following the procedure of Example 5, except substituting 3-(2-furanyl)-2-propenoic acid for 3-chlorocinnamic acid, afforded the title compound: MS(ES) m/e 387.1 [M+H]+. Examples 137-142
Following the procedure of Example 5, except substituting 3-(lH- indol-3-yl)-2-propenoic acid3-(lH-indol-2-yl)-2-propenoic acid, 3-(l-methyl- lH-indol-2-yl)-2-propenoic acid, 3-(benzo[b]thien-3-yl)-2-propenoic acid, 3- (2-benzofuranyl)-2-propenoic acid, and 3-(benzo[b]thien-2-yl)-2-propenoic acid for 3-chlorocinnamic acid, afforded the title compounds:
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(lH- indol-3-yl)-2-propenamide: MS(ES) m/e 435.9 [M+H]+;
N-[3-[2-[bis( 1 -methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-( lH-indol-2- yl)-2-propenamide: MS(ES) m/e 435.9 [M+H]+;
N-[3-[2-[bis( 1 -methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-( 1 -methyl- lH-indol-2-yl)-2-propenamide: MS(ES) m/e 439.9 [M+H]+;
N-[3-[2-[bis( 1 -methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (benzo[b]thien-3-yl)-2-propenamide: MS(ES) m/e 452.3 [M+H]+; N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- benzofuranyl)-2-propenamide: MS(ES) m/e 436.9 [M+H]+; and
N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (benzo[b]thien-2-yl)-2-propenamide: MS(ES) m/e 452.8 [M+H]+.
Example 143 Preparation of N-[4-Methoxy-3-r(2S -(l-methyl-2- pyrrolidinyl)methoxy1phenyl1-3-(3,4-dichlorophenyl)-2-propenamide a) (S)-2-r(2-methoxy-5-nitrophenoxy)methyl]pyrrolidine/REM Resin Adduct REM resin (264.2 g, 0.64 meq/g) was stirred with dimethylformamide ( 500 mL) under argon at RT for 30 min, and a solution of the compound of Preparation 10 (110.9 g 0.47 mol) in dimethylformamide (1 L) was added and the mixture stirred at RT forlό h. resin was collected by filtration, washed with dimethylformamide, dichloromethane, and methanol, and dried in vacuo at RT to afford (272.8 g, 89% yield) of the title adduct with theoretical loading of 0.55 meq/g. b) (S)-2-r(2-methoxy-5-aminophenoxy)methyllpyrrolidine/REM Resin Adduct
The adduct of Example 143(a) (268.1 g) was stirred with dimethylformamide (1 under argon at RT for 30 min and tin(II) chloride dihydrate (133.5 g 0.59 mol) in dimethylformamide (1 L) was added in one portion. The mixture was stirred at RT under argon for 48 h, the resin was collected by filtration, and washed with 10% v/v hydrochlo acid:dioxane 1:1, 10% diisopropylethylamine in dimethylformamide, 50:50 dioxane:wate dioxane, dichloromethane, and methanol. The product was dried in vacuo at RT to const weight to give resin ( 261 g) with a theoretical loading 0.61 meq/g. c) N-r4-Methoxy-3-r(2S -(l-methyl-2-pyrrolidinyl)methoxy]phenyl1- 3-(3,4-dichlorophenyl)-2-propenamide/REM Resin Adduct ^
A double Irori Kans was charged with the resin of Example 143(b) (100 mg) which was treated in dichloromethane with 3-(3,4-dichlorophenyl)-2-propenoic acid (12.3 mmol) followed by l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.36 g) and 1- hydroxybenzotriazole hydrate (1.88 g). The mixture was stirred at RT for 30 min. The Ka were then stirred at RT for 16 h, and washed for approximately 5 min with each of the following 50:50 10% hydrochloric acid:dioxane, 10% diisopropylethylamine in dimethylformamide, 50:50 dioxane: water, dioxane, dichloromethane, and methanol. The Kans was dried in vacuo at RT for 16 h. d) N-f4-Methoxy-3-r(2S)-(l-methyl-2-pyrrolidinyl)methoxylphenvn- 3-(3,4-dichlorophenyI)-2-propenamide
The resin of Example 143(c) was washed for 30 min with dimethylformamide whic was decanted, charged with dimethylformamide (100 mL), and treated with iodomethane (8 mmol). The mixture was stirred at RT for 48 h, the resin was removed and washed for 30 min with each of dimethylformamide, dioxane, dichloromethane, methanol, and diethyl eth The resin was dried in vacuo at RT, removed from the Kans, and treated with 10% triethylamine in dimethylformamide (1 mL) for 16 h with added Amberlyst-A21. The mixture was filtered, treated with 1% triethylamine in dimethylformamide (1 mL), and agitated for 3 h. The solvent was transferred by filtration, and the residue was washed with dimethylformamide (1 mL) for 1 h. The solvent was concentrated in vacuo to afford the titl compound.
Example 144 Preparation of N-r4-Methoxy-3-[(2S)-(l-methyl-2- pyrrolidinyl)methoxy1phenyll-3-(4-methylphenyl)-2-propenamide
Following the procedure of Example 143(c)-(d), except substituting 3- (4-methylphenyl)-2-propenoic acid for 3-(3,4-dichlorophenyl)-2-propenoic acid, afforded the title compound.
Biological Data:
CCR5 Receptor Binding Assay CHO cell membranes (0.25 xlO6 cell equivalents) derived from CHO cells stably transfected with CCR5 were incubated with 0.3 125I- RANTES in a 96 well plate for 45 min at room temperature (final reaction volume 200 ul). The reaction was terminated by filtration and the filters (GF/C) were washed twelve times with a solution of phosphate buffered saline containing 0.1 % bovine serum albumin and 0.05 % NaN3. The radioactivity bound to filters was measured by liquid scintillation spectrometry. Non-specific binding was determined in the presence of unlabelled RANTES (10 or 30 nM) and averages 30-50% of total binding. „
CCR5 Receptor Functional Assay The cellular functional assay used to assess antagonist activity of compounds was
RANTES -induced Ca2+ mobilization in RBL 2H3 cells stably expressing the hCCR5 receptor (RBL 2H3 hCCR5). Agonist activity is determined by Ca2+ mobilization in the same cells which is inhibitable by a selective CCR5 antagonist.
Cells were grown to 80-100% confluency in T-150 flasks and washed with phosphate-buffered saline. Cells were lifted from the flasks by treating with 3 mL of
1 mM EDTA for 3 min at room temperature and diluting to 2 X 10^ cells/mL with
Krebs Ringer Henseleit buffer (KRH; 118 mM NaCl, 4.6 mM KC1, 25 mM NaHCO3, 1 mM KH2PO4 and 11 mM glucose) containing 5 mM HEPES (pH 7.4),
1 mM CaCl2, 1 mM MgCl2 and 0.1% BSA and centrifuged at 200g for 3 min. Cells were resuspended at 2 X 10^ cells/mL in the same buffer with 2 μM Fura-2AM, and incubated for 35 min at 37° C. Cells were centrifuged at 200-x g for 3 min and resuspended in the same buffer without Fura-2AM, then incubated for 15 min at 37° C to complete the hydrolysis of intracellular Fura-2AM, and then centrifuged as before. Cells (106 cells/mL) were resuspended in cold KRH with 5 mM HEPES (pH 7.4), 1 mM CaCl2, 1 mM MgCl2 and 0.1% gelatin and maintained on ice until assayed. For antagonist studies, aliquots (2 mL) of cells were prewarmed at 37° C for 5 min in 3 mL plastic cuvettes and fluorescence measured in a fluorometer (Johnson Foundation Biomedical Group, Philadelphia, PA, USA) with magnetic stirring and temperature maintained at 37° C. Excitation was set at 340 nm and emission set at 510 nm. Various concentrations of antagonists or vehicle were added and fluorescence monitored for -15 sec to ensure that there was no change in baseline fluorescence, followed by the addition of 33 nM RANTES. Maximal Ca2+ attained after 33 nM RANTES stimulation was calculated as described by Grynkiewicz et al., (1985). The percent of maximal RANTES -induced Ca2+ was determined for each concentration of antagonist and the IC50 defined as the concentration of test compound that inhibits 50% of the maximal 33 nM RANTES response, obtained from the concentration-response curves (5-7 concentrations of antagonists).
The compounds of this invention show CCR5 receptor modulator activity having IC50 values in the range of 0.0001 to 100 μM. The full structure/activity relationship has not yet been established for the compounds of this invention. However, given the disclosure herein, one of ordinary skill in the art can utilize the present assays in order to determine which compounds of formula (I) are modulators of the CCR5 receptor and which bind thereto with an IC50 v lue in the range of
0.0001 to 100 μM.
All publications, including, but not limited to, patents and patent applications cited in this specification, are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration it is believed that one skilled in the art can, given the preceding description, utilize the present invention to its fullest extent. Therefore any examples are to be construed as merely illustrative and not a limitation on the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

Claims

What is claimed is:
* 1. A method of treating a CCR5-mediated disease state in mammals which comprises administering to a mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:
Figure imgf000060_0001
wherein: the basic nitrogen in moiety E may be optionally quaternized with C^alkyl or is optionally present as the N-oxide; pl is phenyl, fused bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic heterocyclic ring of 8 to 11 members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur;
L is CONR5';
Rl' and R2' are independently hydrogen, Ci .galkyl, C2_6alkenyl, C2-6alkynyl,
C3.7cycloalkyl, C3.6cycloalkenyl, (CH2)b'NR6'R7', (CH2)b'NR6'COR8', (CH2)b'NR6'CO2R9', (CH2)b'NR6'SO2Rl°', (CH2)b'CONRl l'Rl2', hydroxyCi. 6alkyl, Cχ_4alkoxyalkyl (optionally substituted by a Cχ_4alkoxy or hydroxy group), (CH2)b'CO2C1.6alkyl, (CH2)c C(O)Rl3', CR14'=NOR15', CNR^NORl5', CORl7', CONRl l R12', CONRH'(CH2)dOC1.4alkyl, CONRl l'(CH2)b€O2Rl 8'> CONHNRl9'R20', CONRl l'SO2R21', CO2R22', cyano, trifluoromethyl, NR6'R7', NR6'COR8', NR 3'C0(CH2)b'NR23 R24', NR23'CONR23'R24', NR6'CO2R9', NR6'SO2Rl°', N=CNR23'NR23'R24', nitro, hydroxy, Cι_6alkoxy, hydroxyC 6alkoxy,
Figure imgf000060_0002
OC(O)NR25'R26', SR27', SOR28', SO2R28', SO2NR2 'R30', halogen, Ci .galkanoyl, CO2(CH2)b R31 or Rr is phenyl or Rl' is a 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur, which are optionally substituted by one or two of R3 '; or Rl' is an optionally substituted, fused carbocyclic ring of 5 to 7-members, which may be partly or wholly unsaturated, or R ' is an optionally substituted, fused heterocyclic ring of 5 to 7-members containing 1 to 4 heteroatoms selected from nitrogen, oxygen, or sulfur, which may be partly or wholly unsaturated;
R3' is hydrogen or Ci _6alkyl;
R4' is hydrogen, C galkyl, C galkylCONH, or halogen;
R5' is hydrogen or Cj.galkyl;
R14'5 R15'; Rl6' R17'; R18', R19' R20', R23', R24', R27', and R3V m independently hydrogen or Ci.galkyl;
R^' and R7' are independently hydrogen or Cj_6alkyl, or R^' and R7' together with the nitrogen to which they are attached, forms a 5- to 6-membered heterocyclic ring, which may optionally be substituted by an oxo group, and, when there are six members, may optionally contain in the ring one oxygen or one sulfur atom; R8' is hydrogen, Cj_6alkyl, or C^alkoxy alkyl;
R9', R2!', and R28' are independently C^alkyl;
RIO' is C^alkyl or phenyl;
R 1 ' and R 2' are independently hydrogen or Ci .galkyl, or R 1 and Rl2' together with the nitrogen to which they are attached form a 5- to 6-membered saturated heterocyclic ring which, when there are 6 ring members, may optionally contain in the ring one oxygen or one sulfur atom;
Rl3' is Cι_4alkyl, optionally substituted by a Ci _6alkoxy;
R22' is hydrogen or Cj.galkyl optionally substituted with one or two substituents selected from Cj.galkyl, C^alkoxy, hydroxy, or NR^'R7';
R25' and R2^' are independently hydrogen or Cj.galkyl, or R25 and R2"' together with the nitrogen to which they are attached form a 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom;
R29' and R3^' are independently hydrogen or Cj.galkyl, or R29' and R30' together with the nitrogen to which they are attached form 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or one sulfur atom;
R32' is hydrogen, Cj.galkyl, C3_6cycloalkyl, C3_6cycloalkenyl, hydroxyCj. 6alkyl,
Figure imgf000061_0001
CONR33'R34'; cθ2R35', cyano, aryl, trifluoromethyl, NR3" R37', nitro, hydroxy, Cj.galkoxy, Ci .galkanoyl, acyloxy, or halogen;
R33', R 4', R35', R36'5 and R37' ^ independently hydrogen or Cj.galkyl; a' is 1, 2, or 3; b' is 1, 2, 3 or 4; c' is O, 1, 2 or 3; d' is 1, 2 or 3;
E represents (a):
Figure imgf000062_0001
in which
B is oxygen, S(O)c, CR7=CR8, or CR7R8, or B is NR9;
Rl and R2 are independently hydrogen or Ci .galkyl; alternatively B(CRlR2)a is OCR1R2CR1(OH)CR1R2 or OCR1R2CR1(OCOCH3)CR1R2;
R3 and R4 are independently hydrogen, C galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include Cι _6alkyl, aryl, CONR10Rπ, NR10RH, hydroxy, OCOR12, NHCOC0-6alkyl where alkyl is optionally substituted by OH, NHCOCF3, NHSO2Rl3, and
Figure imgf000062_0002
R5 is hydrogen, Ci .galkyl, aryl, CN, CONRl5Rl6, CO2RI7, trifluoromethyl, NHCO2RI8, hydroxy, Ci .galkoxy, benzyloxy, OCH2CO2C!_6alkyl, OCF3, S(O)dRl9, SO2NR20R21 or halogen;
R^ is hydrogen, Ci .galkyl, aryl, trifluoromethyl, hydroxy, C^alkoxy or halogen, or R6 taken together with R5' forms a group D where D is (CR22R23)e or D is (CR22R23)f-G where G is oxygen, sulfur or CR22=CR23, CR22=N, =CR22O,
=CR22S, or =CR22-NR23;
R7, R8, Rl°, RU, R12, R15, R16, R17, R20, R21, R22, and R23 are independently hydrogen or Ci .galkyl;
R9 is hydrogen, C galkyl, or phenylCμgalkyl; Rl3, Rl , R18, and R19 are independently Cj.galkyl; a is 1, 2, 3, or 4; b is 1 or 2; c and d are independently 0, 1 or 2; e is 2, 3 or 4; f is O, 1, 2 or 3; alternatively, E represents (b):
Figure imgf000063_0001
R24, R25, R26, R27, R28, R29, R31 , and R32 ^g independently hydrogen or Cι_6alkyl;
R is hydrogen, Cj_6alkyl, or C3_7cycloalkyl;
R33 is hydrogen, C^alkyl, trifluoromethyl, hydroxy or halogen, or R33 and
R5' together form a group -K- where K is (CR3 R35)j or K is (CR34R 5)j -M and M is oxygen, sulfur, CR 4=CR35, CR34=N, or N=N;
J is oxygen, CR36R37, or NR38, or J is a group 8(0)^;
R34, R35, R36; R37; ancl R38 arc independently hydrogen or Ci.galkyl; g is 1, 2 or 3; h is 1, 2 or 3; i is 2, 3, or 4; j is 0, 1, 2, or 3; k is 0, 1 or 2; alternatively, E represents (c):
Figure imgf000063_0002
in which:
Q is oxygen, S(O)n, CR44=CR45, CR44R45, or Q is NR46;
R and R4^ are independently hydrogen or Ci .galkyl; R41 is a group of formula (d):
Figure imgf000063_0003
(CH2)0 (CH2 2)/Pp ( ^C-"H '22)'q
N - (d)
or R41 is a group of formula (e):
Figure imgf000064_0001
R42 is hydrogen, C galkyl, aryl, CN, CONR48R49, CO2R50, trifluoromethyl,
NHCO2R51, hydroxy, C^alkoxy, benzyloxy, OCH2CO2Cι.6alkyl, OCF ,
S(O)sR52, SO2NR53R54, or halogen;
R43 is hydrogen or R43 together with R5 forms a group R where R is
CR55=CR56, CR55=CR56CR55R56, or (CR55R56)t;
R44, R45, R46, R48, R49, R50, R53, R54, R55, and R56 are independently hydrogen or Cj.galkyl;
R47 is hydrogen, Cj.galkyl, or 03.7 cycloalkyl;
R51 and R52 are independently Ci .galkyl; l is O, 1, 2, or 3; m is 1 or 2; n is 0, 1 , or 2 o, p, and q are independently integers having the value 1, 2, or 3; r is 0,1, 2, or 3; s is 0, 1, or 2; t is 2 or 3; alternatively, E represents (f):
Figure imgf000064_0002
R57 and R58 are independently hydrogen or Ci .galkyl;
R59 and R^0 are independently hydrogen, Ci .galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C galkyl, aryl, CONR61R62, NR61R62, hydroxy, OCOR63, NHCOC0_6alkyl where alkyl is optionally substituted by OH, NHCOCF3, NHSO2R64, and
NHCO2R65;
T is -(CR66R67)V- or -O(CR66R67)w-;
W is oxygen, S(O)x, NR68, or W is CR69=CR70 0r CR69R70; R61, R62, R63, R66, R67 R68, R69, and R70 are independently hydrogen or Cι_6alkyl;
R64 and R65 are independently Cj.galkyl; u is 1 to 4; v is 2 or 3; w is 1, 2, or 3; x is 0, 1 or 2; alternatively, E represents a group (g):
Figure imgf000065_0001
R71 is an optionally substituted 5 to 7-membered saturated or partially saturated heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur or R71 is an optionally substituted 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulfur;
R72 is hydrogen, Ci .galkyl, aryl, CN, CONR74R75, CO2R76, trifluoromethyl, NHCO R77, hydroxy, C^alkoxy, benzyloxy, OCH2CO2Cι _6alkyl, OCF3, S(O)zR78, SO2NR79R80, or halogen;
R73 is hydrogen, Ci.galkyl, hydroxy, C galkoxy or halogen, or R73 and R5' taken together from a group -X- where X is (CR8lR82)aa or X is (CR8lR82)ab-Y and
Y is oxygen, sulfur or CR81=CR82;
R74, R75, R76, R79, R80, R81, and R82 are independently hydrogen or Cι _ galkyl;
R77 and R7 are independently C^alkyl; y is 1 or 2; z is O, l, or 2; aa is 2, 3 or 4; ab is O, 1, 2 or 3; alternatively, E represents group (h):
Figure imgf000065_0002
R87 (h);
R83 and R84 are independently hydrogen or Cj.galkyl;
R85 and R86 are independently hydrogen, C galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C^galkyl, aryl, CONR88R89, NR90R91, hydroxy, OCOR92, NHCOC0_6alkyf where alkyl is optionally substituted by OH, NHCOCF3, NHSO2R93, and NHCO2R94;
R87 is hydrogen or C^alkyl, C galkoxy, or halogen, or R87 together with R5' forms a group -AA- where AA is (CR95R96)ad or AA is (CR95=CR96)ae-AB and
AB is oxygen, sulfur, CR95=CR96, CR95=N, CR95NR96 or N=N;
Z is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur;
R88, R89, R90, R91, R92, R95, and R96 are independently hydrogen or Cι_ galkyl;
R93 and R94 are independently Ci.galkyl; ac is 0 to 4; ad is 1, 2 or 3; ae is 0, 1 or 2; alternatively, E represents group (i):
Figure imgf000066_0001
R97 and R98 are independently hydrogen, C^alkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include Cι_6alkyl, aryl, CONR1°2R1°3, NR^R105, hydroxy, OCOR106, NHCOCQ. galkyl where alkyl is optionally substituted by OH, NHCOCF3, NHSO2 R107, and
NHCO2R108;
R99 and R100 are independently hydrogen or Cl-6alkyl;
R10 is hydrogen or Cj.galkyl or Rl01 and R5' together form a group -AD- where AD is (CR109Rl l°)ai or AD is (CR109Rl 10)aj-AE and AE is oxygen, sulfur or CRl09=CRl lO;
AC is oxygen, CR1 1 iR1 12 or NR1 13 or AC is a group S(O)ak; R1Q2 Rl03t Rl04 Rl05> R106 Rl09 RI IO. RI H R112f and Rl 13 are independently hydrogen or Cj.galkyl;
R 1 °7 and R J °8 are independently C 1 -όalkyl; af is O, 1, 2, 3, or 4; ag is 1, 2, or 3; ah is 1, 2, 3 or 4; ai is 2, 3 or 4; aj is 0, 1, 2, or 3; and ak is 0, 1 or 2.
2. The method of claim 1 wherein the compound of formula (I) is selected from a subgenus of formula (l
Figure imgf000067_0001
Formula (la) wherein:
Rl', R2', R3', R4', Pl, a', L, R24, R25, R26, R27, R28, R29, R30, R31, R32 R33, J, g, and h are defined in claim 1.
3. The method as claimed in claim 1 wherein the compound is selected from:
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-phenyl-2- propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[4-Methoxy-3-[(2S)-(l-methyl-2-pyrrolidinyl)methoxy]phenyl]-3-(4- methylphenyl)-2-propenamide;
N-[4-Methoxy-3-[(2S)-(l-methyl-2-pyrrolidinyl)methoxy]phenyl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- chlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide hydrochloride; N-[3-[2-(2,2,6,6-Tetramethylpiperidin-l-yl)ethoxy]-4-methoxy-phenyl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[l-[2-[Bis(l-methylethyl)amino]ethyl]-l,2,3,4-tetrahydroquinol-7-yl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3- chlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3- chlorophenyl)-2-propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(3- chlorophenyl)-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxy-phenyl]-3-(3- chlorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- chlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l -methylethy l)amino]propoxy] -4-methoxyphenyl] -3-(4- chlorophenyl)-2-propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(4- chlorophenyl)-2-propenarnide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxy-phenyl]-3-(4- chlorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-[(3,4- methylenedioxy )pheny 1] -2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[(3,4- methylenedioxy)phenyl]-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-[(3,4- methylenedioxy)phenyl]-2-propenamide;
N- [3 - [2-(N-Cyclohexyl-N-isopropy lamino)ethoxy ] -4-methoxy-phenyl] -3 - [(3,4- methylenedioxy)phenyl]-2-propenamide;
N- [3 - [2- [B is ( 1 -methy lethyl)amino]ethoxy ] -4-methoxyphenyl] -3 -(3 ,4- difluorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(3,4- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide ; N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(3,4- difluorophenyl)-2-propenamide;
N- [3 - [2-(N-Cyclohexyl-N-isopropylamino)ethoxy ] -4-methoxy-phenyl] -3 -(3 ,4- difluorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(2- naphthalenyl)-2-propenamide;
N-[3-[3-[Bis( 1 -methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxy-phenyl]-3-(2- naphthalenyl)-2-propenamide;
(E)-N- [3- [2- [B is ( 1 -methylethyl)amino] ethoxy] -4-methoxyphenyl] -3-(3 - chloropheny l)-2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethyl]-2-oxo-(3H)-benzoxazol-5-yl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[4-[2-[Bis(l-methylethyl)amino]ethyl]-3,4-dihydro-3-oxo-2H-l,4- benzoxazin-6-yl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[4-[2-[Bis( 1 -methylethyl)amino]ethyl]-3,4-dihydro-2H- 1 ,4-benzoxazin-6-yl]- 3-(3,4-dichlorophenyhl-2-propenamide;
N-[2,3-Dihydro-l-[2-[bis(l-methylethyl)amino]ethyl]-lH-indol-6-yl]-3-(3,4- dichlorophenyl)-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(5- indolyl)-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl)-3-(6- indolyl)-2-propenamide;
(E)-»#»-Dimethyl-N-[3-[2-[bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]- 3-phenyl-2-propenamide;
(Z)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl)-«- (acetylamino)-3-(3,4-dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)]-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(5,6,7,8- tetrahydronaphth-2-yl)-2-propenamide trifluoroacetate salt;
N-(Spiro[benzofuran-3(2H),4'-piperidin]-5-yl)-3-(3,4- dichlorophenyl)-2-propenamide; N-[l'-(Isopropyl)spiro[benzofuran-3(2H)4'-piperidin]-5-yl]-3-(3,4- dichlorophenyl)-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]- 3-(4-chloro-3-methylphenyl)-2-propenamide;
N-[3-[2-[Bis( 1 -methylethyl)amino]ethoxy]-4-methoxypheny]-3-(4- fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[4- (trifluoromethy l)pheny 1] -2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-[3- (trifluoromethyl)phenyl]-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[3- (trifluoromethy l)pheny 1] -2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-[3- (trifluoromethy l)pheny 1] -2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- chlorophenyl)-2-propenamide ;
N-[3-[3-[Bis(l -methylethyl)amino]propyl] -4-methoxyphenyl] -3 -(2- chlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l -methy lethyl)amino]propoxy ] -4-methoxyphenyl] -3 -(2- chlorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,4- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,4- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,4- dichlorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,6- dichlorophenyl)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,6- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,6- dichloropheny 1)] -2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,5- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,5- difluorophenyl)-2-propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,5- difluorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,5- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,5- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,5- difluorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,4- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,4- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,4- difluorophenyl)]-2-propenamide(SB-383258);
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3- fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3- fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3- fluorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2-chloro-6- fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2-chloro-6- fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2-chloro-6- fluorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4-bromo-2- fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4-bromo-2- fluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4-bromo-2- fluorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4-chloro-2- fluoropheny l)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4-chloro-2- fluoropheny l)-2-propenamide ; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4-chloro-2- fluorophenyl)]-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2-chloro-4- fluorophenyl)-2-propenamide
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2-chloro-4- fluorophenyl)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2-chloro-4- fluorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2,6- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2,6- difluorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,6- difluorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- bromophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- bromophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- bromophenyl)] -2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4-chloro-3- nitrophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4-chloro-3- nitrophenyl)-2-propenamide;
N-[3-[2-[Bis(l -methylethy l)amino]ethoxy] -4-methoxyphenyl] -3 - [4-( 1 - methylethyl)phenyl]-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-[4-(l- methylethyl)pheny 1] -2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-[4-(l- methylethyl)phenyl]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(5-bromo-2- methoxyphenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(5-bromo-2- methoxyphenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-([l,l'- biphenyl] -4-y l)-2-propenamide ; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-([l,l'- biphenyl] -4-yl)-2-propenamide ;
*
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2,3-dihydro- 1 H-inden-5-yl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3-bromo-4- fluorophenyl)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3-bromo-4- fluorophenyl)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3-bromo-4- fluorophenyl)]-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,5- dichlorophenyl)-2-propenamide trifluoroacetate ;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,5- dichlorophenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,5- dichlorophenyl)]-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dimethylphenyl)-2-propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- dimethylphenyl)-2-propenamide
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3,4- dimethylphenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(4- cy anophenyl)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(4- cyanophenyl)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4- cy anophenyl)] -2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-fluoro-3- phenyl-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-2-fluoro-3- phenyl-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-2-fluoro-3- phenyl-2-propenamide ;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-[4-chloro- 3-(trifluoromethyl)phenyl]-2-propenamide; (E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-»-methyl-2-propenamide;
(E)-N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-[4- (trifluoromethyl)phenyl]-2-propenamide;
N-[3-[2-Acetoxy-3-[bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3- (3,4-dichlorophenyl)-2-propenamide;
N-[3-[2-(4-Hydroxy-2,2,6,6-tetramethylpiperidin-l-yl)ethoxy]- 4-methoxyphenyl]-3-(3,4-dichlorophenyl)-2-propenamide;
N-[l'-(l-Methylethyl)spiro[benzofuran-3(2H)4'-piperidin]-5-yl]-3-(3,5- dichlorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3-thienyl)-2- propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3-thienyl)-2- propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(3-thienyl)-2- propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(3-thienyl)-2- propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]-3-(3-thienyl)-2- propenamide;
N-[3-[2-[Bis(l -methylethy l)amino] ethoxy] -4-methy lpheny 1] -3 - (4-pyridinyl)-2- propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(4-pyridinyl)-2- propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3-furanyl)-2- propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methylphenyl]-3-(3-furanyl)-2- propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3-furanyl)-2- propenamide;
N-[3-[2-(cis-2,6-Dimethylpiperidin-l-yl)ethoxy]-4-methoxyphenyl]-3-(3-furanyl)-2- propenamide;
N-[3-[2-(N-Cyclohexyl-N-isopropylamino)ethoxy]-4-methoxyphenyl]-3-(3-furanyl)-2- propenamide;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(2-thienyl)-2- propenamide; N-[3-[3-[Bis(l-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-(2-thienyl)-2- propenamide;
*
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2-furanyl)-2- propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(lH-indol-3- yl)-2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(lH-indol-2-yl)-2- propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(l-methyl-lH-indol- 2-yl)-2-propenamide ;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3- (benzo[b]thien-3-yl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2-benzofuranyl)-2- propenamide; and
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(benzo[b]thien-2-yl)- 2-propenamide.
4. The method of claim 1 wherein the CCR5-mediated disease state is selected from COPD, asthma and atopic disorders, rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, and HIV.
5. A compound of formula (I) selected from: N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[3-[2-[Bis(l-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2- naphthalenyl)-2-propenamide hydrochloride;
N-[3-[2-(2,2,6,6-Tetramethylpiperidin-l-yl)ethoxy]-4-methoxy-phenyl]-3-(3,4- dichlorophenyl)-2-propenamide ;
N-[3-[3-[Bis(l-methylethyl)amino]propyl]-4-methoxyphenyl]-3-(3,4- dichlorophenyl)-2-propenamide;
N-[3-[2-(4-Hydroxy-2,2,6,6-tetramethylpiperidin-l-yl)ethoxy]- 4-methoxyphenyl]-3-(3,4-dichlorophenyl)-2-propenamide; and
N-[l'-(l-Methylethyl)spiro[benzofuran-3(2H)4'-piperidin]-5-yl]-3-(3,5- dichlorophenyl)-2-propenamide.
PCT/US1999/017117 1998-07-28 1999-07-28 Propenamides as ccr5 modulators Ceased WO2000006153A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002338804A CA2338804A1 (en) 1998-07-28 1999-07-28 Propenamides as ccr5 modulators
EP99937585A EP1100495A4 (en) 1998-07-28 1999-07-28 Propenamides as ccr5 modulators
JP2000562008A JP2002521441A (en) 1998-07-28 1999-07-28 Propenamide as a CCR5 modulator

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9440598P 1998-07-28 1998-07-28
US60/094,405 1998-07-28

Publications (1)

Publication Number Publication Date
WO2000006153A1 true WO2000006153A1 (en) 2000-02-10

Family

ID=22244982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017117 Ceased WO2000006153A1 (en) 1998-07-28 1999-07-28 Propenamides as ccr5 modulators

Country Status (4)

Country Link
EP (1) EP1100495A4 (en)
JP (1) JP2002521441A (en)
CA (1) CA2338804A1 (en)
WO (1) WO2000006153A1 (en)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007020A2 (en) 1999-07-27 2001-02-01 Boehringer Ingelheim Pharma Kg Carboxylic acid amides, medicaments containing these compounds and the use and production thereof
WO2004039764A1 (en) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel amide compounds with mch antagonistic effect and medicaments comprising said compounds
EP1264820A4 (en) * 2000-03-14 2004-09-15 Fujisawa Pharmaceutical Co Novel amide compounds
WO2006054793A1 (en) * 2004-11-19 2006-05-26 The New Industry Research Organization Benzofuran compound and pharmaceutical composition containing the same
WO2006129679A1 (en) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
US7160546B2 (en) 1995-06-06 2007-01-09 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7211672B2 (en) 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2007049771A1 (en) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2007058322A1 (en) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
WO2007132846A1 (en) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7501123B2 (en) 2004-03-12 2009-03-10 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
CN100519524C (en) * 2005-09-29 2009-07-29 中国人民解放军军事医学科学院毒物药物研究所 Indole acrylic acid derivative and its use for preparing immune inhibitor
US7579347B2 (en) 2001-12-10 2009-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7592358B2 (en) 2004-04-14 2009-09-22 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US7696201B2 (en) 2006-08-15 2010-04-13 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786107B2 (en) 2006-08-18 2010-08-31 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
US7820817B2 (en) 2004-05-28 2010-10-26 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7858790B2 (en) 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
US7863449B2 (en) 2004-11-29 2011-01-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7879834B2 (en) 2004-08-19 2011-02-01 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
US7951950B2 (en) 2005-02-24 2011-05-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7973162B2 (en) 2007-10-03 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8003660B2 (en) 2006-02-22 2011-08-23 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2364982A1 (en) 2003-04-18 2011-09-14 ONO Pharmaceutical Co., Ltd. Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
EP2385040A1 (en) 2003-03-14 2011-11-09 ONO Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US8158792B2 (en) * 2007-11-21 2012-04-17 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
US8263605B2 (en) 2006-02-22 2012-09-11 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
EP2546234A1 (en) 2004-09-13 2013-01-16 Ono Pharmaceutical Co., Ltd. Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US10117931B2 (en) 2009-04-28 2018-11-06 Kameran Lashkari Methods for treatment of age-related macular degeneration
WO2021222069A1 (en) 2020-04-27 2021-11-04 Incelldx, Inc. Methods and compositions for treating cytokine storm infections, including covid-19, by inhibiting ccr5/ccl5 interaction

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101063462B1 (en) * 2002-08-29 2011-09-08 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
JP2012006837A (en) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd 2-indoleacrylamide analogue

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES464943A1 (en) * 1977-12-10 1978-09-01 Cuatrecasas Labor M Procedure for the obtaining of amidas of pharmacological interest. (Machine-translation by Google Translate, not legally binding)
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
US5373019A (en) * 1988-02-06 1994-12-13 Boehringer Mannheim Gmbh Pharmaceutical lactam compositions for inhibition of erythrocyte and thrombocyte aggregation
WO1999019303A1 (en) * 1997-10-13 1999-04-22 Yamanouchi Pharmaceutical Co., Ltd. Pyrazole derivatives
WO1999032100A2 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3167556A (en) * 1963-11-19 1965-01-26 Olin Mathieson Basic derivatives of anilides
US3201401A (en) * 1964-09-17 1965-08-17 Olin Mathieson Aminoalkoxy and aminoalkylthioanilide compounds
GB1099829A (en) * 1965-02-09 1968-01-17 Squibb & Sons Inc Derivatives of aromatic amines
US4343813A (en) * 1980-08-28 1982-08-10 Pfizer Inc. Carboxamide compounds as SRS-A antagonists
US4296129A (en) * 1980-10-29 1981-10-20 Pfizer, Inc. (Carboxyacylamino)phenylalkenamides and esters thereof as SRS-A antagonists
GB9300083D0 (en) * 1993-01-05 1993-03-03 Roussel Lab Ltd Chemical compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES464943A1 (en) * 1977-12-10 1978-09-01 Cuatrecasas Labor M Procedure for the obtaining of amidas of pharmacological interest. (Machine-translation by Google Translate, not legally binding)
US5373019A (en) * 1988-02-06 1994-12-13 Boehringer Mannheim Gmbh Pharmaceutical lactam compositions for inhibition of erythrocyte and thrombocyte aggregation
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
WO1999019303A1 (en) * 1997-10-13 1999-04-22 Yamanouchi Pharmaceutical Co., Ltd. Pyrazole derivatives
WO1999032100A2 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AGRA. UNIV. J. RES., vol. 9, 1960, pages 15 - 19, PART 1, SEE RN 131239-53-7 AND 131239-54-8 *
ANN. MED., vol. 27, no. 5, 1995, pages 537 - 541 *
CASDATA, CA abstract no. 117:63005, NATIONAL HEART AND LUNG INSTITUTE, "Immunosuppressants for treatment of lung diseases". *
CASDATA, CA abstract no. 118:147852, HALL et al., "The synthesis of pyrido (4,3-b)carbazoles from diphenylamine derivatives: alternative routes to and relay syntheses of ellipticines and olivacines". *
CASDATA, CA abstract no. 124:172731, DE VRIES J.E., "Immunosuppressive and anti-inflammatory properties of interleukin 10". *
CASDATA, CA abstract no. 130:311815, YAMANOUCHI PHARMACEUTICAL CO., LTD. "Preparation of pyrazole derivatives as calcium-release dependent calcium channel inhibitors and inhibitors of interleukin-2 (IL-2) production". *
CASDATA, CA abstract no. 131:87834, TAKEDA CHEMICAL INDUSTRIES, LTD. "Preparation of benzoxepinecarboxamines, benzocycloheptenecarboxamides, naphthalenecarboxamines and related compounds as CCR5 antagonists". *
CASDATA, CA abstract no. 73:76840, IMPERIAL CHEMICAL INDUSTRIES LTD. "Alkanolamine derivatives with .beta.- adrenergic blocking activity". *
CASDATA, CA chemical abstract 90:87093, LABORATORIA MARTIN CUATRECASAS S.A., "Cinnemanilides of pharmacological interest". *
CHEMICAL ABSTRACTS, vol. 55, no. 23, 13 November 1961, Columbus, Ohio, US; abstract no. 24660F, GEORGE ET AL: "Condensation of malono-o, m and p-chloroanilic acids with aldehydes. V. With vanillin and piperonal" page 689; column 2; XP002922108 *
J. CHEM. SOC. PERKIN TRANS. 1, vol. 24, 1992, pages 3439 - 3450, SEE RN 146308-27-2 *
KRAPCHO ET AL: "Immunosuppressive activity of dimethyl aminopropyl thiocinnamanilide and related compounds", J. MED. CHEM., vol. 12, January 1969 (1969-01-01), pages 164 - 166, XP002922105 *
See also references of EP1100495A4 *

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160546B2 (en) 1995-06-06 2007-01-09 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
WO2001007020A2 (en) 1999-07-27 2001-02-01 Boehringer Ingelheim Pharma Kg Carboxylic acid amides, medicaments containing these compounds and the use and production thereof
EP1264820A4 (en) * 2000-03-14 2004-09-15 Fujisawa Pharmaceutical Co Novel amide compounds
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7582657B2 (en) 2001-12-10 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7579347B2 (en) 2001-12-10 2009-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7211672B2 (en) 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EA009040B1 (en) * 2002-10-31 2007-10-26 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Novel amide compounds with mch antagonistic effect and medicaments comprising said compounds
WO2004039764A1 (en) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel amide compounds with mch antagonistic effect and medicaments comprising said compounds
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
EP2385040A1 (en) 2003-03-14 2011-11-09 ONO Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
EP2364982A1 (en) 2003-04-18 2011-09-14 ONO Pharmaceutical Co., Ltd. Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US7501123B2 (en) 2004-03-12 2009-03-10 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US7592358B2 (en) 2004-04-14 2009-09-22 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US7820817B2 (en) 2004-05-28 2010-10-26 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8497295B2 (en) 2004-08-19 2013-07-30 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
US7879834B2 (en) 2004-08-19 2011-02-01 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
US8258148B2 (en) 2004-08-19 2012-09-04 Vertex Pharmaceutical Incorporated Spiroindoline modulators of muscarinic receptors
US8367691B2 (en) 2004-08-19 2013-02-05 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
EP2546234A1 (en) 2004-09-13 2013-01-16 Ono Pharmaceutical Co., Ltd. Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient
US8084492B2 (en) 2004-11-19 2011-12-27 The New Industry Research Organization Benzofuran compound and pharmaceutical composition containing the same
WO2006054793A1 (en) * 2004-11-19 2006-05-26 The New Industry Research Organization Benzofuran compound and pharmaceutical composition containing the same
US7863449B2 (en) 2004-11-29 2011-01-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7951950B2 (en) 2005-02-24 2011-05-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2006129679A1 (en) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
CN100519524C (en) * 2005-09-29 2009-07-29 中国人民解放军军事医学科学院毒物药物研究所 Indole acrylic acid derivative and its use for preparing immune inhibitor
WO2007049771A1 (en) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
EP2657235A1 (en) 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2007058322A1 (en) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
US8304423B2 (en) 2006-02-22 2012-11-06 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8003660B2 (en) 2006-02-22 2011-08-23 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8263605B2 (en) 2006-02-22 2012-09-11 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
WO2007132846A1 (en) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
US7858790B2 (en) 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US7696201B2 (en) 2006-08-15 2010-04-13 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786107B2 (en) 2006-08-18 2010-08-31 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7973162B2 (en) 2007-10-03 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8158792B2 (en) * 2007-11-21 2012-04-17 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
US8536189B2 (en) 2007-11-21 2013-09-17 Janssen Pharmaceutica Nv Spiropiperidines for use as tryptase inhibitors
US10117931B2 (en) 2009-04-28 2018-11-06 Kameran Lashkari Methods for treatment of age-related macular degeneration
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2021222069A1 (en) 2020-04-27 2021-11-04 Incelldx, Inc. Methods and compositions for treating cytokine storm infections, including covid-19, by inhibiting ccr5/ccl5 interaction

Also Published As

Publication number Publication date
EP1100495A1 (en) 2001-05-23
EP1100495A4 (en) 2002-09-25
CA2338804A1 (en) 2000-02-10
JP2002521441A (en) 2002-07-16

Similar Documents

Publication Publication Date Title
WO2000006153A1 (en) Propenamides as ccr5 modulators
WO2004011427A2 (en) Substituted benzanilides as modulators of the ccr5 receptor
WO2000006146A1 (en) Substituted anilide compounds and methods
EP1313477A1 (en) Compounds and methods
US6930185B2 (en) Melanin-concentrating hormone antagonist
US7229986B2 (en) Melanin-concentrating hormone antagonist
WO2004010943A2 (en) Substituted benzanilides as modulators of the ccr5 receptor
US6399656B1 (en) Compounds and methods
US7115750B1 (en) Melanin concentrating hormone antagonist
WO2004010942A2 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
KR20010014419A (en) Compounds and Methods
EP1037635A1 (en) Compounds and methods
EP1219294A1 (en) Melanin concentrating hormone antagonists
JP2012111784A (en) Substituted arylamine compound and their use as 5-ht6 modulator
CA2318100A1 (en) Chemokine receptor antagonists and methods of use therefor
JPH11514671A (en) 1,4-Di-substituted piperidines as muscarinic antagonists
WO2000040239A1 (en) Compounds and methods
JP2002371059A (en) Melanin-agglutinating hormone antagonist
EP3582783B1 (en) 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US20040038982A1 (en) Compounds and methods
EP1343796A2 (en) Compounds and methods
JP2002241274A (en) Melamine-aggregating hormone antagonist
TW200524871A (en) Chemical compounds
HK40115276A (en) Flavonoid derivatives with gabaa receptor activity and methods of use
MXPA01001023A (en) Substituted anilide compounds and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2338804

Country of ref document: CA

Ref country code: CA

Ref document number: 2338804

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09744601

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 562008

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999937585

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999937585

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999937585

Country of ref document: EP